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Abstract 
Mitochondrial disorders constitute a clinically and genetically heterogeneous group of 
diseases that arise as a result of dysfunction of the mitochondrial respiratory chain. They can 
be caused by mutations in either the nuclear or mitochondrial DNA. In this study, three 
patients with clinical suspicion of mitochondrial disease were investigated by whole exome 
sequencing (WES), identifying the homozygous splice site mutation SURF1 c.106+1G>C in 
patient 1. This mutation, which was demonstrated to cause skipping of exon 2 in SURF1, was 
concluded to be the genetic cause of the Leigh syndrome like phenotype in the patient. 
Patients 2 and 3 were further investigated by massively parallel sequencing (MSP) of mtDNA 
from fibroblasts using a PCR free protocol for the preparation of mtDNA enriched samples. 
Sequencing resulted in uniform and ultra-deep coverage (>40,000) of the entire mtDNA 
genome, demonstrating that the PCR free approach is the method of choice when analyzing 
mitochondrial DNA by MSP. In parallel, analysis of mtDNA from muscle from patient 3 
revealed the novel and nearly homoplastic deletion m.6211_8681del, which was concluded to 
be the cause of disease in the patient. This deletion was also identified in mtDNA from the 
patient’s blood and skin tissues, but it was present in too low levels of heteroplasmy to be 
detected by MSP.   
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1 Introduction 
1.1 The scope of medical genetics 
Medical genetics as we know it today had its beginning around 1900 when A. E. Garrod 
published his work on alkaptonuria [1]. Although many genetic disorders were known and 
described before that, for example Huntington’s disease, Garrod was the first to publish an 
account of a case of recessive inheritance in humans and to suggest a molecular basis of the 
disease. During the following hundred years, medical genetics grew from a small field of 
research concerned with a few rare hereditary disorders to a specialty of medicine that 
involves the diagnosis and management of many diseases, both rare and common [2]. This 
development did not, however, start to accelerate before the last decade of the 20
th
 century, 
with the ongoing Human Genome Project contributing significantly to the progress. Now that 
the human genome is mapped and a reference sequence is available, several genes can be 
studied as an entity, rather than one gene at a time. Medical genetics has thus become an 
important part of the broader field of genomic medicine. 
In contrast to genetics, which is the study of specific genes and their effects, genomics is the 
study of the functions and interactions of all the genes in the genome, including interactions 
with environmental factors [3]. Genomic medicine has therefore a broader goal than medical 
genetics. It aims at explaining and treating not only those relatively rare conditions that follow 
one of the Mendelian patterns seen in single-gene disorders, but also common conditions such 
as schizophrenia, heart disease, diabetes, bipolar disorder, and Parkinson’s disease. These 
complex disorders, which are also called “multifactorial” because of the many factors that 
contribute to them, affect almost two of every three individuals during their lifetime [4]. 
The main task of medical genetics is essentially to explain the causal relationship between 
genotype and phenotype on the one hand, and to give counseling and manage the phenotype 
on the other. Its starting point is therefore the human genome. Since the human nuclear 
genome and the mitochondrial genome are different in several important ways, some of which 
will be discussed later, these two will be treated separately in this introductory part.  
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1.2 The nuclear genome 
The six billion DNA base pairs that make up the nuclear genome in somatic cells are divided 
between 23 chromosome pairs and twined around octamers of histone proteins, forming a 
dense network of DNA and protein called chromatin. It is only during cell division that 
chromatin is condensed to such a degree that it appears as visible chromosomes under the 
microscope, otherwise it is variably distributed throughout the cell nucleus. Chromosomes 
differ both in size and gene content, and even though genes are located throughout any given 
chromosome, they tend to cluster in specific regions. A consequence of this is that the clinical 
severity of a chromosomal abnormality depends not only on the type of the defect, but also on 
where in the genome it is located. 
The estimated number of genes contained in the genome was drastically reduced with the 
completion of the initial draft sequence of the human genome in 2001, and the number has 
continued to fall ever since. In fact, current estimates indicate that the number may be as low 
as 19,000 protein-coding genes [5]. This means that protein-coding regions make up only one 
percent, or approximately 30 MB, of the entire human genome, divided between 180,000 
exons [6]. While most of the remaining regions may have other biochemical and regulatory 
functions [7] and can therefore not be considered unimportant or superfluous, the vast 
majority, about 85 percent, of the mutations with large effects on disease-related phenotypes 
are located in the exons [8]. Most of these mutations are so-called rare variants that – in 
contrast to common variants or polymorphisms – have a minor allele frequency (MAF) of less 
than one percent in the population [9].  
1.2.1 Classification of variants 
If we compare the DNA sequence of any two individuals, we find that they are 99.9 percent 
identical. Still it is the small variable fraction that contributes to the genetically determined 
differences among humans. The mutations responsible for this fraction are mostly 
polymorphisms, while only a small part of them are rare variants. Although the “common 
disease-common variant” hypothesis has been popular for a long time, the correlation 
between the frequency of a variant and the effect it has on human health is not such that 
common diseases are only caused by common variants [10]. Rare and generally deleterious 
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variants may actually stand for much of the genetic component of the common multifactorial 
diseases [11].  
Variants can be classified into three categories based on their size: numerical chromosomal 
variants, which alter the number of chromosomes in the cell; structural chromosomal variants, 
which affect the structure of individual chromosomes; and genetic variants, which alter 
individual genes [12]. The most common type of numerical chromosomal aberrations is 
aneuploidy; a deviation from the normal number of 46 chromosomes. This abnormality, 
which is usually caused by meiotic nondisjunction
1
, is rarely compatible with life [13]. One of 
the exceptions is trisomy 21, which is seen in ~95 percent of all cases of Down syndrome 
[14].  
Structural chromosomal aberrations – whether deletions, duplications, translocations, 
insertions, or inversions – are formed by chromosomal breakage or unequal crossing-over 
[15]. A range of these abnormalities can result in disease, but then they are usually 
unbalanced rearrangements. This means that the complete chromosome set is no longer 
present, so that genetic information is either added or missing. Deletions, duplications, and 
insertions are all unbalanced rearrangements, and they can lead to several severe disorders, 
like Prader-Willi and Angelman syndromes [16]. In contrast, balanced rearrangements, where 
the full complement of DNA material is retained, are generally not associated with disease.  
Genetic variants are usually classified as deleterious or normal based on their phenotypic 
effect, or, if this is not known, as variants of unknown significance (VUS). Variants that may 
result in premature truncation of the gene product – such as deletions, insertions, non-sense 
and frame shift variants, or variants that alter the splice site – are generally regarded as 
deleterious [17]. But for missense mutations, where one amino acid is substituted for another, 
it is often difficult, or even impossible, to predict the effect they will have on the phenotype. 
The reason for this is partly that the physicochemical differences between any two amino 
acids may or may not be so great as to have an impact on protein function. However, there are 
certain clues that do indicate whether a given missense variant disrupts the function or not. 
One of these is the variant’s position within the protein. If, for example, the variant is located 
within a functional domain or if it affects an amino acid that has already been shown to 
contain a pathogenic mutation, then it is likely to be pathogenic [18]. Another important clue 
is the conservation between species, as mutations occurring in positions that are conserved 
                                                 
1
 Nondisjunction is the failure of sister chromatids to separate properly during cell division. 
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throughout evolution are likely to be deleterious [19]. “Sorting intolerant from tolerant” 
(SIFT) and “polymorphism phenotyping” (PolyPhen) are two bioinformatics tools that use 
evolutionary conservation as a basis for predicting whether non-synonymous changes are 
likely to disrupt protein function or not [18]. 
1.2.2 Mendelian inheritance 
In contrast to multifactorial diseases, the underlying genetic causes of many Mendelian 
disorders are well understood. This is because the phenotypic effects of the variants 
underlying Mendelian diseases are less affected by environmental factors than complex 
disorders. In addition, these effects are often distinct and very severe, allowing for their early 
and accurate identification [20]. But the fact that the phenotypic consequences are largely 
unaffected by the environment also means that they follow inheritance patterns that accord 
with the rules of probability. Patterns of inheritance basically fall into one of three groups: 
autosomal, X-linked
2
, and mitochondrial. Here we will briefly mention autosomal and X-
linked inheritance, while mitochondrial inheritance, which differs from Mendelian inheritance 
in many important respects, will be discussed later.  
The inheritance patterns of single-gene (or Mendelian) disorders depend mainly on two 
factors: whether the phenotype is recessive or dominant, and whether the causative gene 
variant is located on an autosome or a sex chromosome. A phenotype is recessive when it is 
manifest if the underlying genotype is homozygous or compound heterozygous – that is, if 
both alleles are mutated, either by harboring the same mutation or different mutations. If, on 
the other hand, one mutated allele causes the phenotype to be expressed, the phenotype is 
considered dominant. 
The other important factor determining the pattern of inheritance is the location of the gene 
variant causing the phenotype. The clinical phenotype of an autosomal mutation is the same 
in both males and females. But for X-linked mutations, that is not always the case. Since 
males normally have only one X-chromosome, they can neither be homozygous nor 
heterozygous for a mutated X-linked allele, only hemizygous. In consequence, males are 
generally much more vulnerable to X-linked recessive disorders then females, who are 
usually affected only if they have two mutated alleles. When it comes to X-linked dominant 
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 Because Y-linked disorders are very few in number (less than 10 Y-linked diseases are described in the OMIM 
database), Y-linked inheritance is not included in this categorization. 
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disorders, the situation is even more so as some of these disorders are lethal in males only. 
Approximately ten different X-linked dominant male-lethal disorders have been described in 
the literature so far [21].  
Online Mendelian Inheritance in Man (OMIM; www.omim.org) is a comprehensive online 
database of all known Mendelian disorders and known causative genetic variants. To date, 
more than 4000 phenotypes with known genetic basis are described in OMIM, and new 
descriptions are continuously added [22]. 
1.3 Dissecting the molecular basis of single-gene disorders 
Diagnosis of a genetic disease is usually established based on a combination of clinical 
manifestations, family history, and biochemical and genetic tests, such as karyotyping or 
array-based comparative genomic hybridization (aCGH), or the selection of candidate genes 
for testing [23]. Over the last few years, however, whole exome sequencing (WES) has 
proved to be a powerful and cost-effective tool for dissecting the genetic basis of disease, 
greatly improving both diagnosis and genetic counseling [24]. When whole exome 
sequencing is performed to identify the genetic cause of a disease, the whole process of 
identifying the genetic cause often proceeds in three steps: whole exome sequencing, data 
filtering of the called variants, and verification by Sanger sequencing. What follows is a brief 
description of the principles behind each of these three steps. 
1.3.1 Whole exome sequencing 
Since most rare and deleterious variants are located in the protein-coding regions, which 
constitute only 1 percent of the entire human genome, whole exome sequencing (WES) is a 
more rapid and cost-effective method for routinely identification of rare and novel variants 
than most genome-wide approaches [6]. In general, different WES approaches follow the 
same four-step process regardless of the capture method and sequencing platform used. These 
major steps are: library preparation, hybridization to capture arrays, massively parallel 
sequencing of eluted fragments, and bioinformatics [25, 26]. As outlined in Figure 1, genomic 
DNA is first randomly shared to construct a library, the fragments of which are flanked with 
adapters to allow sequencing. Next, the library is enriched for exons by hybridization to 
biotinylated DNA or RNA baits in the presence of blocking oligonucleotides complementary 
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to the adapters. The hybridized fragments are then captured (for example by streptavidin 
coated magnetic beads), washed, and amplified. The library is finally sequenced by massively 
parallel sequencing, followed by mapping and variant calling [26]. 
 
Figure 1 Workflow of exome sequencing. The figure shows the major steps of WES as explained in the text. A more 
detailed description of the computational part of the WES process is found in 2.2.2. Dark blue fragments: exons; orange 
fragments: biotinylated DNA or RNA baits. Adapters and the blocking nucleotides are not shown (from Bamshed et al. [26]). 
1.3.2 Data filtering 
On average, whole exome sequencing identifies at least 20,000 single nucleotide variants 
(SNVs) per individual [26]. A significant challenge of using exome sequencing to find 
disease-causing alleles is therefore to pick out the pathogenic variants from the background of 
benign variants and sequencing errors. Typical filtering steps that are applied to filter out non-
causative variants are summarized in Figure 2, which is modified from Stitziel et al. [27]. 
What follows is a brief discussion of the different steps along with key assumptions made at 
each of them. 
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Figure 2 Typical filtering steps applied to exome sequencing projects to reduce the number of candidates for disease-
causing variants. 
 
About 3 million SNVs per genome are discovered using whole-genome sequencing [28]. 
Assuming that causal variants are coding and ignoring regulatory elements and other non-
coding variants outside of exon definitions, targeted sequencing of exons excludes more than 
99% of the detected variants. By focusing only on non-synonymous (amino acid-altering) 
changes, up to 75% of the roughly 20,000 exon variants can further be removed [29]. The 
assumption here is that causative variants will change the amino acid sequence, ignoring rare 
cases of functional synonymous changes [30]. But not all protein-altering variants are 
considered. Often, only those are retained that are predicted to be deleterious to protein 
function; either because a truncated protein product results, as is the case with nonsense, 
splice site, and frame shift mutations; or because the mutation interrupts protein function in 
other ways, as is the case with deleterious missense mutations. SIFT and PolyPhen identify 
missense mutations that are likely to be deleterious based on the level of conservation of the 
mutated nucleotide and amino acid. Under the assumption that pathogenic changes are rare in 
the healthy population, non-synonymous variants with a minor allele frequency (MAF) of 
more than 1% are usually filtered out. This step currently reduces the list of putative causal 
variants to about 200 to 500 [27]. 
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To further restrict the search, a recessive or dominant model of disease is imposed when one 
of them is more likely than the other as indicated by the pedigree or the disease itself. If the 
pedigree suggests a recessive mode of inheritance, a putative causal variant must either be 
present in a homozygous or compound heterozygote state. On the other hand, a dominant 
model requires affected individuals to be heterozygous for the same variant [31]. 
This short overview is not meant to be exhaustive or to outline the exact sequential 
application of the different filtering steps; it is only meant to illustrate the effectiveness with 
which simple filtering can drastically reduce the number of potential disease-causing variants. 
The goal is to reduce the list to a single putative variant or gene that can further be analyzed 
and verified by functional studies.      
1.3.3 Sanger sequencing 
Because exome sequencing does have some technical limitations and errors may therefore 
occur, like poor coverage or inaccurate calling, Sanger sequencing is often required to verify 
the findings one is left with after filtering. Developed by Sanger and his colleagues in 1977, 
Sanger sequencing was the most widely used sequencing method before massively parallel 
sequencing became commercially available, and it is still widely used today, although in a 
modified manner.  In their original publication, Sanger et al. [32] used four separate reactions 
for sequencing, each reaction containing a DNA template, a primer, DNA polymerase, 
reaction buffer, radioactively labeled deoxynucleotides (dNTPs), and one of the four chain-
terminating dideoxynucleotides (ddNTPs). When they initiated DNA synthesis, extension 
products of different lengths terminated with a ddNTP at the 3’ end would result. They would 
then employ gel electrophoresis to separate the extension products by size at a resolution of 
one base pair, so that the sequence could be read fairly easy, from bottom to top, by 
comparing the relative positions of the different bands among the four lanes (Figure 3). 
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Figure 3 A simplified overview of the traditional Sanger method. 
 
Cycle sequencing is a modified version of the traditional Sanger method that is widely used 
today for automated long read DNA sequencing. The principle is essentially the same but the 
method differs in at least two important respects. Firstly, instead of radioactively labeled 
dNTPs, cycle sequencing uses ddNTPs tagged with different fluorescent dyes, each of which 
emits a unique wavelength when excited by light. Thus, all the four labeled ddNTPs (dye 
terminators) are combined in one reaction that is subjected to cycles of annealing, extension, 
and denaturation in a thermal cycler [33].  
Secondly, the DNA sequencing products are not separated by gel electrophoresis but by 
capillary electrophoresis in which a denaturing liquid polymer is used. During capillary 
electrophoresis, the negatively charged extension fragments are forced into the capillaries 
through a high voltage charge that is applied to the buffered sequencing reaction. Shortly 
before reaching the positive electrode, the fluorescently labeled extension products, which are 
separated by size based on their total charge, move through a laser beam that causes the dyes 
on the fragments to fluoresce. The emitted fluorescence signals are then detected by an optical 
detection device and converted into digital raw data. Finally, a data analysis software 
processes the raw data and displays it as an electropherogram – a sequence of peaks in four 
colors, each representing one of the four bases. The main advantage of using capillary 
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electrophoresis for separation is its flexibility and the ease with which it can be incorporated 
into automated instruments [34]. 
1.4 Mitochondrial genetics 
Although the mitochondrial genome is extremely small compared to the nuclear genome, 
mutations in the mitochondrial genome is an important cause of inherited disease [35]. But 
despite the small size, mitochondrial genetics is complicated by several features that 
distinguish it from nuclear genetics and that present unique experimental and clinical 
challenges. Some of these features and challenges as they relate to inheritance patterns, 
sequencing, and diagnosis will be discussed in this second part of the introduction. But what 
follows first are some basic facts about mitochondrial genetics. 
1.4.1 The mitochondrial genome  
Mitochondria are found in all nucleated cells and function primarily as generators of cellular 
ATP by oxidative phosphorylation (OXPHOS). Most cell types contain hundreds of 
mitochondria, each harboring several copies of mitochondrial DNA (mtDNA) [36]. The 
mitochondrial genome consists of a circular double-stranded DNA molecule of 16.6 kb, 
which encodes 13 mRNAs that are all translated within the organelle, plus 22 tRNAs and 2 
rRNAs. The 13 polypeptides encoded are protein subunits of the electron transport chain 
complexes I, III, IV, and V, while the tRNAs and rRNAs are necessary components of the 
mitochondrial translation machinery (Figure 4). But the vast majority of respiratory chain 
subunits, translation machinery components, and almost all of the factors involved in mtDNA 
replication, transcription, translation, and repair are encoded by the nuclear genome [37]. 
From a genetic point of view, the respiratory chain is thus unique, as it is formed by two 
separate but complementary genetic systems, the mitochondrial and the nuclear genomes 
(Figure 5). 
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Figure 4 Structure of human mitochondrial DNA. The 13 protein-coding genes found in the mitochondrial genome are 
ND1-ND6 (blue), which encode the subunits of respiratory chain complex I; COI-COIII (red) which encode the subunits of 
complex IV; ATPase6 and 8 (yellow) which encode subunits 6 and 8 of complex V; and Cyt b (purple) which encodes 
cytochrome b of complex III. The 22 tRNA genes are indicated by the single letter code of the corresponding amino acids, 
while the two rRNA genes, 12S and 16S, are marked in green. The D-loop, sometimes referred to as the control region, is a 
stretch of non-coding mtDNA. It is the most polymorphic region of the human mitochondrial genome (from Zeviani et al. 
[38]). 
 
 
Figure 5 Nucleus-mitochondrion interactions. The nucleus encodes for most of the protein subunits of the respiratory 
chain complexes. In addition, nucleus-encoded factors act in the assembly and turnover of the respiratory chain, in the 
synthesis and transport of cofactors and substrates, and in the maintenance and expression of mtDNA (from Zeviani et al. 
[38]). 
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Both the small size and the fact that it is covalently closed circular are very significant 
structural properties that mtDNA shares with bacterial plasmids. A third property that it has in 
common with bacterial plasmids is that the mitochondrial genome is not twined around 
proteins and packaged as chromatin. In this respect, it differs from both the nuclear genome 
and bacterial chromosomal DNA (as opposed to bacterial plasmids). Although the latter is not 
intertwined with proteins in the same way as nuclear chromosomes, it is nevertheless 
constantly interacting with and even wound around multiple proteins that help to form and 
maintain the supercoiled state [39]. Since mitochondrial DNA and bacterial plasmids share 
several important aspects in their structural organizations, a simple bacterial plasmid isolation 
protocol can be utilized for enrichment of mtDNA (see 2.5). 
1.4.2 Mitochondrial inheritance 
Diseases that result from mitochondrial mutations show a pattern of inheritance that differs 
radically from Mendelian inheritance. This distinctive inheritance pattern is mainly because of 
three unique features of mitochondria: vegetative segregation, homoplasmy and 
heteroplasmy, and maternal inheritance.  
Alleles of nuclear genes do not segregate during mitosis, which means that, for example, 
heterozygous cells produce heterozygous daughters. The reason for this is that nuclear 
genomes are said to be “stringent” genomes in which a) each chromosome replicates exactly 
once during interphase, and b) both daughter cells receive one copy of all the 46 
chromosomes [40]. In contrast, alleles of mitochondrial genes undergo vegetative segregation, 
meaning that they segregate during mitosis as well as meiosis [41]. The basic reason 
underlying vegetative segregation is that both replication and partitioning of mitochondrial 
genomes are so-called relaxed processes. At cell division, the many copies of mtDNA in each 
of the mitochondria in the cell replicate and sort randomly between the daughter 
mitochondria. In addition, the daughter mitochondria themselves are distributed randomly 
between the two daughter cells [41]. 
The second unique feature of mitochondria is homoplasmy and heteroplasmy. Homoplasmy 
means that all copies of the mitochondrial DNA in a cell, a tissue, or an organism are 
identical; heteroplasmy means that there exists a mixture of two or more mitochondrial 
genotypes [35]. Three factors contribute to mtDNA diversity. Firstly, ~25% of healthy 
individuals inherit a mixture of normal and variant mtDNA; secondly, mtDNA has an 
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estimated mutation rate of ~5-15 times that of the nuclear genome, partly because of 
proximity to the electron transport chain that is the major intracellular source of oxidative free 
radicals, and partly because of limited mtDNA protection and repair mechanisms; and thirdly, 
the level of variant mtDNA can change during life through relaxed replication and 
partitioning [42]. The presence of heteroplasmy is of particular interest when we consider 
mtDNA variants that lead to disease, as the disease phenotype is expressed only when the 
percentage of mutant molecules exceeds a critical threshold level (Figure 6). Depending on 
the type of mutation and the tissue type, this level is usually in the range of 70-90% [43]. 
 
 
Figure 6 The effect of heteroplasmy on disease (from Longo et al. [44]). 
 
Maternal inheritance is the last feature underlying the distinct inheritance pattern of diseases 
that result from mutations in the mitochondrial genome. Although paternal inheritance of 
mtDNA in humans has been reported before [45], this is the exception rather than the rule 
[46]. The widely accepted view is that in the cells of most animals mtDNA is inherited solely 
from the oocyte from which the animal develops [47]. In mammals, paternal mitochondria 
derived from sperm generally enter the cytoplasm of the oocyte where they shortly co-exist 
with an excess of maternal mitochondria [48]. However, the paternal mitochondria and their 
DNA are subsequently eliminated and not transmitted to the offspring. Two hypotheses have 
been proposed to explain the underlying mechanism of maternal inheritance of mtDNA in 
mammals. The “simple dilution model” suggests that the paternal mtDNA, because it is 
present at a much lower copy number, is simply diluted away by the excess of maternal 
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mtDNA and is therefore not detectable in the offspring [49]. According to the “active 
degradation model”, paternal mitochondria are selectively degraded by ubiquitination to 
actively prevent transmission to the next generation [50]. 
1.5 Sequencing the mitochondrial genome 
Even though sequencing of the whole mitochondrial genome is routinely practiced, it 
nevertheless presents with several challenges that must be overcome in order to produce high 
quality sequences. One of these challenges is the presence of nuclear DNA sequences of 
mitochondrial origin (NUMTs), which are the result of mtDNA transfers to the nucleus (see 
4.3.3). If using PCR to amplify mtDNA, primers must be carefully designed to avoid co-
amplification of NUMTs as they pose a real problem for accurate sequence interpretation 
[51]. A second challenge is the universal presence of low levels of heteroplasmy in human 
mitochondrial DNA [42]. In order to detect low-level heteroplasmic mtDNA variants, it is 
necessary to use sequencing methods that achieve very great depth of coverage per base 
position. A third challenge is the use of PCR amplification itself. Despite the high number of 
mitochondrial genomes in each cell, mtDNA only constitutes a small portion of total cellular 
DNA. For this reason, it is necessary to enrich samples for mtDNA before sequencing. PCR 
amplification is the most efficient and most commonly used method for enrichment, but may 
produce artifacts since many cycles are needed for sufficient enrichment, which again can 
lead to biased results [52]. 
To overcome the third challenge, Quispe-Tintaya et al. [52] designed a simple, fast, and cost-
effective method for preparation of samples that are enriched for mtDNA. This method, 
which we applied in our study, consists of two steps: extraction of mitochondrial DNA using 
a standard kit for isolation of bacterial plasmids followed by additional purification using 
solid-phase reversible immobilization (SPRI) paramagnetic beads. The principles underlying 
these two techniques are described in 2.5. 
1.6 Mitochondrial disorders  
Mitochondrial disorders constitute a clinically heterogeneous group of diseases that arise as a 
result of dysfunction of the mitochondrial respiratory chain. They can be caused by mutations 
in either the nuclear or mitochondrial DNA. Due to the complexity of mitochondrial genetics 
and the fact that mitochondria are vital components of all nucleated cells, the clinical 
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manifestations of mtDNA disorders are extremely diverse (Table 1). They range from lesions 
that affect only one organ or tissue, such as the optic nerve in Leber’s hereditary optic 
neuropathy (LHON), to lesions that are more widespread including encephalomyopathies, 
myopathies, and cardiopathies, to complex multisystem syndromes that may present at any 
age [38]. While many affected individuals display a number of clinical features that fall into a 
discrete syndrome, such as chronic progressive external ophthalmoplegia (CPEO) and 
myoclonic epilepsy with ragged red fibers (MERRF), some individuals present with a 
considerable variety of clinical symptoms that do not fit into one specific category. One 
illustration of this is the overlapping spectrum of disease phenotypes that result from 
mutations in the nuclear POLG gene, which is the most common nuclear gene causing 
mitochondrial disorders [53, 54]. 
 
 
Table 1 Phenotypic expression of mitochondrial diseases. One way to classify the extremely diverse phenotypic 
expressions of mitochondrial disorders is to split them into the two categories of neurological and systemic manifestations 
(from Zeviani et al. [38]). 
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1.6.1 Mitochondrial disorders of nuclear origin 
A major feature that distinguishes mitochondrial disorders of nuclear origin from those of 
mtDNA origin is the mode of inheritance, as the former group follows a Mendelian pattern of 
inheritance while the latter does not. Even in cases where mitochondrial syndromes 
characterized by the presence of mtDNA abnormalities are inherited as Mendelian traits, the 
underlying genetic cause is usually the existence of mutations in nuclear genes affecting the 
integrity of the mitochondrial genome [55]. Although more than 90% of the mitochondrial 
proteins related to the respiratory chain are encoded by the nuclear genome, the number of 
mitochondrial disorders shown to be caused by defects in nuclear genes is still small [55]. 
Mutations have been identified in only about 150 of the estimated 1,500 nuclear genes 
associated with mitochondria [54]. 
A classification has been proposed that organizes these disorders into four categories based on 
the target of the respective gene defect [56]. The first category consists of the nuclear genes 
responsible for mtDNA stability. These are all related to replication of mtDNA, by encoding 
enzymes or factors that are either part of the mitochondrial replication machinery or supply 
the building blocks of mtDNA. The second category includes all genes encoding structural 
components of the respiratory chain complexes. The third group consists of nuclear genes 
involved in expression, assembly, and turnover of the OXPHOS complexes, usually 
complexes III and IV. In infancy, the most frequent manifestation of complex IV deficiency is 
Leigh syndrome [57]. The last category consists of the disorders caused by defects in nuclear 
genes that are indirectly related to OXPHOS. One such disorder is X-linked sideroblastic 
anemia
3
 and ataxia caused by mutations in the iron mitochondrial exporter ABC7, which 
controls the generation of cytosolic iron-sulfur proteins [38, 55]. 
1.6.2 Mitochondrial disorders of mtDNA origin 
In contrast to mitochondrial disorders of nuclear origin, those of mtDNA origin are all 
directly related to the electron transport chain. The reason for this is that each of the 37 genes 
contained in the mitochondrial genome either encodes a protein subunit of the respiratory 
chain or a component of the mitochondrial translational machinery needed to make the 
                                                 
3
 Sideroblastic anemia is a form of anemia in which the bone marrow produces ringed sideroblasts rather than 
healthy erythrocytes. Sideroblasts are atypical, abnormal nucleated erythroblasts (precursors to mature 
erythrocytes) with granules of iron accumulated in perinuclear mitochondria. In sideroblastic anemia, the body 
has iron available but cannot incorporate it into hemoglobin. 
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subunits. These disorders, with all their complexity with regard to inheritance and clinical 
manifestations, are often classified into two major categories: (i) disorders due to large-scale 
rearrangements of mtDNA, and (ii) disorders due to mtDNA point mutations [58].  
Most large-scale rearrangements of mtDNA are sporadic. They can either be partial deletions 
of mtDNA or, less frequently, partial duplications. Both types are usually heteroplasmic as 
they exist together with normal mtDNA. Large-scale rearrangements are mainly associated 
with Kearn-Sayre syndrome (KSS), progressive external ophthalmoplegia (PEO), and 
Pearson’s syndrome [38, 58] (see 4.6). On the other hand, mtDNA point mutations are 
typically maternally inherited. Characteristic of these mutations is that they affect highly 
conserved nucleotides/amino acids or that they cause loss of function of the protein product. 
When these mutations are heteroplasmic, which is usually but not always the case, the 
severity of the disease tends to correlate with the degree of heteroplasmy. This is for example 
seen in neurogenic weakness, ataxia, and retinitis pigmentosa (NARP), a syndrome mainly 
associated with the mutation m.8993T>G in MT-ATP6. In contrast to many heteroplasmic 
point mutations, the clinical expression of disorders caused by homoplasmic mutations is 
often stereotypical and restricted to one tissue, as is the case in LHON. Over 95% of LHON 
patients worldwide carry one of three mtDNA point mutations: m.11778G>A (ND4), 
m.14484T>C (ND6), or m.3460G>A (ND1), all of which affect genes encoding complex I 
subunits of the respiratory chain [59]. 
1.6.3 Leigh syndrome 
Leigh syndrome (LS) is a severe neurodegenerative disease that typically arises in infancy, 
affecting 1 in 40,000 newborns [60, 61]. This condition is characterized by progressive loss of 
mental and motor abilities; characteristic MRI findings in the basal ganglia, thalamus, 
cerebellum, or brain stem; high lactate levels in blood or cerebrospinal fluid; and signs and 
symptoms of lesions in brain stem or basal ganglia, such as ataxia, dystonia, optic atrophy, 
hypotonia, respiratory failure, chorea, and swallowing or feeding difficulties [57]. LS is 
genetically heterogeneous, and so the inheritance pattern of the disorder varies accordingly. 
Thus, it is maternally inherited when caused by mutations in mtDNA genes, such as MT-
ATP6 encoding subunit 6 of ATP synthase (complex V). LS can also be inherited in a 
Mendelian manner; either X-linked due to a deficient pyruvate dehydrogenase complex 
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caused by mutations in PDHA1, or autosomal recessive due to mutations in nuclear genes 
encoding respiratory chain subunits or assembly proteins [57]. 
Cytochrome c oxidase (COX) deficiency is one of the most common biochemical 
abnormalities found in LS patients [62]. COX is the terminal component (complex IV) of the 
respiratory chain and catalyzes the transfer of electrons from reduced cytochrome c to oxygen 
(Figure 7). The complex is composed of 13 subunits, 10 of which are encoded by nuclear 
genes and three by mtDNA genes. Assembly of the subunits is controlled by at least six 
nuclear genes [63]. Loss-of-function mutations of one of these “COX assembly genes”, 
SURF1, are the best documented autosomal cause of LS worldwide [62, 64]. To date, more 
than 70 mutations in SURF1 have been reported in patients with LS [57].  
 
 
Figure 7 Oxidative phosphorylation and the respiratory chain. Oxidative phosphorylation is the last stage of cellular 
respiration. The energy released by oxidation of organic molecules is conserved in the reduced electron carriers NADH and 
FADH2 (not shown). Electrons from these carriers are then transferred by complexes I and II to the electron carrier 
ubiquinone (or coenzyme Q, CoQ) before they are carried on to cytochrome c by complex III. Finally, cytochrome c oxidase 
(COX, complex IV) catalyzes the transfer of electrons from the reduced cytochrome c to oxygen, which is the last electron 
acceptor in the respiratory chain. In the course of electron transfer, the large amount of energy released is used to translocate 
protons across the mitochondrial inner membrane from inside out, thus generating an electrochemical gradient across the 
membrane. The energy stored in this gradient drives the synthesis of ATP by ATP synthase (complex V) (from Zeviani et al. 
[38]).   
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1.6.4 Kearn-Sayre syndrome 
Kearns-Sayre syndrome (KSS), first described in 1958, is a rare multisystem disorder which 
belongs to the group of mitochondrial cytopathies
4
 [65]. The diagnosis of KSS is made on the 
basis of three obligatory characteristics: onset of symptoms before 20 years of age, 
progressive external ophthalmoplegia (PEO), and pigmentary retinopathy. In addition, KSS 
patients have at least one of the following symptoms: cardiac conduction defects, cerebellar 
ataxia, or abnormally high levels of protein (>100 mg/dL) in the cerebrospinal fluid [66, 67]. 
The molecular basis underlying the disease is sporadic large-scale rearrangements of the 
mitochondrial DNA, usually deletions varying in location, size, and percentage. The most 
common deletion, found in approximately one third of KSS patients, is 
m.8470_13446del4977. Extending over 4,977 base pairs, this deletion affects twelve 
mitochondrial genes [66, 68].  
1.7 Clinical description of patients 
Three patients with clinical suspicion of mitochondrial disease were studied in the present 
work (Table 2). Patient 1 is a 9 year old boy born to healthy consanguineous Pakistani 
parents. The delivery was normal. He has two brothers of 13 and 15 years of age who are both 
healthy. At the age of two, he was short of stature and delayed in his motoric development, 
but growth hormone levels were normal. At four years of age, the patient presented with 
additional clinical manifestations, including ataxia, microcephaly, general hirsutism, general 
dystrophy, elevated protein and pyruvate levels in cerebrospinal fluid (CSF), increased lactate 
levels in blood and CSF, and strabismus. Examination of muscle tissue carried out at the 
Nijmegen Centre for Mitochondrial Disorders (NCMD) revealed a decreased complex II and 
IV activity but no mtDNA mutations were found. Nor did the muscle biopsy show any signs 
of ragged-red fibers or any other morphological changes of the mitochondria. He slowly 
developed symptoms of retinopathy and progressive external ophthalmoplegia (PEO), such as 
impaired eye movement, drooping eyelids (ptosis), and salt-and-pepper fundus. Other clinical 
findings were demyelinating neuropathy, cognitive failures, and MRI images showing signal 
changes in deep grey matter and the brain stem. The patient does not suffer from cardiopathy. 
The clinical manifestations are suggestive of Leigh syndrome (LS). 
                                                 
4
 Mitochondrial cytopathies represent a heterogeneous group of multisystem disorders which preferentially affect 
the muscle and nervous systems. 
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Patient 2 is a Norwegian boy born in 2009 to healthy non-consanguineous Norwegian parents. 
His 7 years old brother and 11 years old sister are both healthy. No family history of ataxia or 
neurological disease is known. At 14 months of age, he was 9 months behind in his motoric 
development. Later he also developed progressive ataxia with intention tremor. MR imaging 
revealed no cerebellar atrophy but he had elevated tau protein levels (302 ng/L; reference: 
110-177.5 ng/L) in CSF. Lactate and pyruvate levels were both normal. Electromyography 
detected changes in the electrical muscle activity (myopathy), and at 4.5 years of age, he 
showed signs of partial PEO. No firm diagnosis has yet been established. 
Patient 3 is a Turkish boy born in 1999 to consanguineous healthy parents. He has a brother 
with epilepsy and a healthy sister. At the age of 9, the main symptoms were poor growth, 
exercise intolerance, and general fatigue. Chromosome analysis, blood test, and head MRI 
were all normal. But later, signs of retinopathy, ataxia, and PEO appeared. In addition, serum 
levels of lactate were elevated (6.3 mmol/L; reference: 0.5-2.2 mmol/L). He also had 
abnormally high levels of protein (587 mg/dL; reference: 15-60 mg/dL) in CSF. At 15 years 
of age, retinitis pigmentosa (RP) was confirmed by electroretinography (ERG). A second 
head MRI revealed cerebral leukodystrophy and lesions in the brain stem, cerebellum, and 
basal ganglia. The clinical picture is indicative of a KSS diagnosis. 
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Table 2 Clinical presentation and genetic mutations in three patients with suspected mitochondrial disease. The genetic defects in patients 1 and 3 were identified in the current study. 
Patient Born Sex Ethnicity CS Neuromuscular Metabolic 
Brain MRI 
lesions 
Others Mutation 
Clinical 
diagnosis 
           
1 2006 M Pakistani Yes Ataxia 
Myopathy 
PEO 
RP 
Elevated 
lactate and 
pyruvate 
levels 
Basal ganglia 
Brain stem 
Cerebellum 
- SURF1 
c.106+1G>C 
LS 
           
2 2009 M Norwegian No Aataxia 
Myopathy 
- Cerebral cortex? Increased  
tau in CSF 
- ? 
           
3 1999 M Turkish Yes Aataxia 
PN 
RP 
Leukodystrophy 
Elevated 
lactate 
Basal ganglia 
Brain stem 
White matter 
Cerebellum 
- m.6211_8681del KSS 
           
M, male; CS, consanguineous family; PEO, progressive external ophthalmoplegia; RP, retinitis pigmentosa; PN, progressive neuropathy; KSS, Kearns-Sayre syndrome; LS, Leigh syndrome. 
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1.8 Aim of thesis 
The main aim of this thesis was to identify the causative genetic variants in three patients 
suspected to have a mitochondrial disease. Since the majority of respiratory chain subunits, 
translation machinery components, and almost all of the factors involved in mtDNA 
replication, transcription, translation, and repair are encoded by nuclear genes, the nuclear 
genomes of the three patients were first analyzed to identify the genetic variants most likely to 
be responsible for the clinical phenotypes. Thereafter, the mitochondrial genomes were 
analyzed for the same purpose. A sub-aim of this thesis was therefore to evaluate the 
suitability of using massively parallel sequencing for the detection of disease-causing 
mutations in the mitochondrial genome.    
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2 Methods  
2.1 Blood sampling and DNA/RNA extraction 
Blood from the three patients and their healthy parents was sampled in K/EDTA blood 
collection vials and DNA was extracted using the QIAsymphony DSP DNA Kit on the 
QIAsymphony SP instrument (Qiagen GmbH) according to manufacturer’s recommendations. 
For RNA extraction, blood from all three families was collected in PAXgene Blood RNA 
tubes and RNA was extracted with the PAXgene Blood RNA Kit (PreAnalytiX GmbH) as 
described in the manufacturer’s protocol. Quantification and purity measurement of the DNA 
and RNA samples were carried out with the NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific). 
2.2 Whole exome sequencing 
Whole exome sequencing (WES) of DNA from all subjects was performed to identify 
potentially disease-causing variants. The samples were prepared by Asbjørn Holmgren at the 
Department of Medical Genetics, Oslo University Hospital, and delivered to the Norwegian 
Sequencing Centre (NSC) for sequencing on the Illumina HiSeq 2000 platform. 
2.2.1 Library preparation and exome capture 
Individual libraries were prepared for each DNA sample by randomly shearing the DNA with 
a Covaris ultrasonicator (Covaris) producing fragments of approximately 150bp. Using the 
SureSelect XT Library Prep Kit (Agilent Technologies), the fragments were end repaired, 3’ 
end adenylated, ligated with paired-end adaptors, and amplified according to the 
manufacturer’s instructions. Hybridization with biotynilated RNA baits and exome capture 
using streptavidin-coated magnetic beads were then performed using the same kit. Finally, the 
amplified exome captured library was quantified with a Qubit 2.0 Fluorometer (Life 
Technologies) and the fragment size distribution was measured in an Agilent 2100 
Bioanalyzer instrument using an Agilent High Sensitivity DNA Chip (Agilent Technologies). 
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2.2.2 Sequencing, alignment, and variant calling 
The captured library was sequenced on an Illumina HiSeq 2000 platform at the NSC. Reads 
that did not pass Illumina’s standard filter were removed prior to alignment, while the 
remaining reads were aligned to the reference human genome (GRCh37/hg19) using 
Burrows-Wheeler Aligner tool (http://bwa.sourceforge.net/). PCR duplicates were removed. 
Approximately 99% of exome targets defined by Agilent were covered, with an average of 
95x coverage per targeted base for each of the samples. Variant calling was performed using 
the Genome Analysis Toolkit (GATK) (https://www.broadinstitute.org/gatk/) and variants 
were annotated with SnpEff (http://snpeff.sourceforge.net/) and VEP 
(http://www.ensembl.org/info/docs/tools/vep/). VCFtools (http://vcftools.sourceforge.net/) 
was used to manipulate variant calling format (VCF) files and the Integrative Genomic 
Viewer (http://www.broadinstitute.org/igv/) was used to visualize the data.  
2.2.3 Analysis and filtering of called variants 
The variant calling format (VCF) files generated were analyzed and filtered with FILTUS 
(http://folk.uio.no/magnusv/FILTUS/). The following genes and variants were filtered out: 
genes that generate false positive signals in exome sequencing [69]; variants seen more than 
two times in 268 exome sequences available in-house; variants with a Phred quality score less 
than 30 (meaning that the accuracy of the base call is less than 99.9%
5
; see 3.3.4); variants 
with minor allele frequency (MAF) greater than 0.01 according to the 1000 Genomes project 
(http://1000genomes.org/),  dbSNP138 (http://ncbi.nlm.nih.gov/SNP) and  Exome Variant 
Server (http://evs.gs.washington.edu/EVS); and variants predicted to be benign/tolerated by 
SIFT (http://sift.jcvi.org/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/). Only 
protein-coding variants were retained, with a special focus on small deletions/insertions and 
missense, nonsense, frameshift, and splice site mutations. Based on the family history of the 
patients, mutations with recessive homozygous mode of inheritance were chosen for further 
examination.  
 
 
                                                 
5
 See: http://www.phrap.com/phred/ 
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2.3 Verification by Sanger sequencing 
To verify the SURF1 mutation detected in patient 1 by whole exome sequencing, we Sanger 
sequenced a 455bp DNA region containing the position of this point mutation. This we did for 
the patient and his parents using the DNA extracted with the QIAsymphony DSP DNA Kit.  
2.3.1 Primer design, PCR amplification and purification  
Primers for PCR amplification were design using the web-based primer design tool Primer3 
(http://bioinfo.ut.ee/primer3/). A DNA sequence of approximately 600bp containing the 
mutation site was pasted into the software and following parameters were chosen: product 
size range 450-600bp; primer length 18-23bp; melting temperature (Tm) 57-70°C; GC content 
30-70%; and max Tm difference between forward and reverse primers 5°C. The DNA 
sequence was also labeled for the software to avoid the common SNPs found in SURF1 as 
defined by Ensebl (http://www.ensembl.org/). In addition, the designed primers were checked 
for sequence similarities in other DNA regions using BLAT (http://genome.ucsc.edu/cgi-
bin/hgBlat) and In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr). Finally, the primers 
were tailed with universal M13 sequences and ordered by Eurofins Genomics (Ebersberg, 
Germany) (Table 3). 
Name Sequence (5'- 3') 
Primer 
size (bp) Tm (°C) GC (%) 
SURF1 Fwd tgtaaaacgacggccagtATGCAGATGCTTCCTGCGTC 20 63.8 55 
SURF1 Rev caggaaacagctatgaccAGCTACCTCTCGCGTTGTGA 20 61.1 55 
 
Table 3 PCR primer sequences for Sanger sequencing. The primer sequence is shown in capital letters, while the universal 
M13 tales are shown in small letters. The length of the amplified fragment is 455 base pairs and occupies the chromosome 
region chr9:133356046-133356500. The melting temperatures were calculated by In-Silico PCR assuming 50 mM salt and 50 
nM annealing oligo concentration. 
 
PCR amplification of the 455bp DNA segment was carried out on a Veriti 96-Well Thermal 
Cycler (Applied Biosystems) according to standard PCR protocols using AmpliTaq Gold 
DNA Polymerase with Gold Buffer (Applied Biosystems). PCR conditions and cycle 
parameters are shown in Table 4. To check the specificity of the designed primers, the 
amplified DNA fragments from the three subjects were run on a 1% agarose gel in 1X TAE 
buffer and visualized with GelRed Nucleic Acid Gel Stain (Biotium) on an ImageQuant Las 
4000 instrument (GE Healthcare Life Sciences). The DNA was then purified on Biomek FXP 
Laboratory Automation Workstation (Beckman Coulter) using the Agencourt AMPure XP 
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system (Beckman Coulter). Paramagnetic beads (see 2.5; Footnote 6) were added in 1.8 
bead:DNA ratio by volume in order to remove primer dimers, excess primers and dNTPs, 
salts and other contaminants. The DNA fragments were washed with 70% ethanol and eluted 
in water.  
Component  Volume (µL)   Stage Temperature Time 
H2O 18.4   Stage 1 96°C 5 min 
Primers (10 µM) 1.0   Stage 2 94°C 30 sec 
10 mM dNTP 0.5     60°C 45 sec 
25 mM MgCl2 1.5     72°C 45 sec 
AmpliTaq Gold (5U/µL) 0.1   Stage 3 72°C 10 min 
10X Gold Buffer 2.5         
DNA (60 ng/µL) 1.0         
Total 25.0         
 
Table 4 PCR conditions and cycle parameters used for PCR amplification. Stage 1, 1 cycle of initial denaturation; stage 
2, 30 cycles of denaturation, annealing and elongation; stage 3, 1 cycle of final extension. The first stage is also necessary in 
order to activate the enzyme. 
2.3.2 Cycle sequencing and purification 
The cycle sequencing was carried out using BigDye Terminator v3.1 Cycle Sequencing Kit 
(Life Technologies) supplied with universal M13 primers. Veriti 96-Well Thermal Cycler 
(Applied Biosystems) was used for the cycle sequencing (Table 5). The samples were then 
purified on the Biomek FXP Laboratory Automation Workstation (Beckman Coulter) using 
Agencourt CleanSEQ (Beckman Coulter). CleanSEQ is a solid-phase reversible 
immobilization (SPRI) paramagnetic bead-based system similar to AMPure but is especially 
design to remove dye-terminators in addition to the other contaminants. This significantly 
improves the final sequencing data quality [70]. 85% ethanol was used for washing before the 
DNA was eluted in 0.05 mM EDTA. 
Component  Volume (µL)   Stage Temperature Time 
H2O 4.75   Stage 1 96°C 10 sec 
5X Sequencing Buffer 2.0     50°C 5 sec 
Ready Reaction Mix 0.25     60°C 4 min 
M13 Primer 1.0   Stage 2 10°C ∞ 
Purified PCR product 2.0         
Total 10.0         
 
Table 5 Conditions and cycle parameters used for cycle sequencing. 5X Sequencing Buffer, Ready Reaction Mix and 
M13 Primer supplied with the BigDye Terminator v3.1 Cycle Sequencing Kit. The BigDye enzyme is contained in the 
reaction mix. Stage 1: 25 cycles of denaturation, annealing and elongation.  
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2.3.3 Capillary electrophoresis and sequence analysis 
Cycle sequencing produces PCR fragments of different sizes. To separate the fragments, the 
samples were subjected to capillary electrophoresis (see 1.3.3) on the 3730xl DNA Analyzer 
(Applied Biosystems). This instrument separates the extension fragments and detects the 
fluorescent ddNTP (dye-terminator) attached to the end of each fragment during cycle 
sequencing. The digital raw data produced were then analyzed using Sequencing Analysis 5.1 
(http://sequencing-analysis.software), which processes the raw data and displays it as an 
electropherogram. 
2.4 Sequencing of transcripts 
The SURF1 splice site mutation we identified with whole exome sequencing was predicted by 
the mutation analysis software Alamut Visual 2.6.1 (Interactive Biosoftware) to cause a skip 
of exon 2. To test this prediction, we used the RNA extracted from the blood samples (see 
2.1) to synthesize cDNA. As described below, the cDNA was PCR amplified, checked on an 
agarose gel, and Sanger sequenced. 
2.4.1 cDNA synthesis and PCR amplification 
Total RNA from patient and parents was reversely transcribed to single-stranded cDNA with 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to 
producer’s specifications. Approximately 800 ng total RNA was used in each 20 µL reaction. 
Reverse transcription was performed in a Veriti 96-Well Thermal Cycler (Applied 
Biosystems) using the following cycling conditions: 10 min at 25°C, 120 min at 37°C, and 5 
min at 85°C. For amplification of the cDNA produced from SURF1 transcripts, primers were 
designed to specifically target exon 1 and 5 of the transcripts in order to detect a potential 
skipping of exon 2 (Table 6). The primer design was carried out manually due to the small 
size and high GC content of the exons. The SURF1 cDNA was amplified with the Platinum 
Taq PCRx DNA Polymerase Kit using MgSO4 in the mix instead of MgCl2 (Table 7). PCR 
mix components and cycling parameters used are summarized in Table 6. The annealing 
temperature (57°) was optimized experimentally. 
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Name Sequence (5'- 3') 
Primer 
size (bp) Tm (°C) GC (%) Exon 
cDNA Fwd TGCGTTGCAGCTGGGGCT 18 68.9 66.7 1 
cDNA Rev CCTCCCGGACAGGGTCCAC 19 67.5 73.7 5 
 
Table 6 Primers used in PCR amplification of cDNA. The forward primer was targeted to exon 1 of the SURF1 transcript, 
while the reverse primer was targeted to exon 5. SURF1 contains 9 exons in total. The full amplicon size – including exon 2 – 
is 422bp; without exon 2 the length of the amplicon  is 370bp. Melting temperatures were calculated by In-Silico PCR 
assuming 50 mM salt and 50 nM annealing oligo concentration. 
 
 
Component  Volume (µL)   Stage Temperature Time 
H2O 14.9   Stage 1 95°C 2 min 
10X PCR buffer 2.0   Stage 2 95°C 45 sec 
10 mM dNTP 0.4   
 
57°C 30 sec 
50 mM MgSO4 0.8   
 
68°C 1 min 
Primers (10 µM) 0.8   Stage 3 4°C  ∞ 
Platinum Taq Polymerase 0.1     
cDNA (40 ng/µL) 1.0     
Total 20.0         
 
Table 7 PCR components and cycling conditions used in PCR amplification of cDNA.  
 
2.4.2 Gel electrophoresis and Sanger sequencing of cDNA 
The amplified cDNA fragments from the three subjects were run for 90 min on a 1.5% 
agarose gel in 1X TAE buffer and visualized with GelRed Nucleic Acid Gel Stain (Biotium) 
on the ImageQuant Las 4000 instrument (GE Healthcare Life Sciences). The gel 
electrophoresis resulted in one band for the patient sample and two bands for the parent 
samples. Of the two bands in the parent samples, the biggest was extracted and purified using 
the Wizard SV Gel and PCR Clean-Up System (Promega) according to manufacturer’s 
instructions. This was not necessary to do for the patient sample as only one band was 
produced. The three samples were then Sanger sequenced following the same procedure as 
described above (2.3.1-2.3.3), consisting of AMPure, cycle sequencing, CleanSEQ, and 
capillary electrophoresis. The sequencing results were finally analyzed with Sequencing 
Analysis 5.1. 
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2.5 Sequencing the mitochondrial genome 
To reliably sequence the mitochondrial genomes of patients 2 and 3, mtDNA enriched 
samples were prepared according to the mtDNA extraction protocol designed by Quispe-
Tintaya et al. [52]. This method consists of two steps: mtDNA extraction using a standard kit 
for isolation of bacterial plasmids, and additional purification using AMPure beads. The 
principles underlying these two techniques are described here. 
Conventional kits for isolation of bacterial plasmids are based on the alkaline extraction 
method described by Birnboim and Doly [71]. After harvesting and resuspension, bacterial 
cells are lysed in NaOH and sodium dodecyl sulfate (SDS). SDS solubilizes the phospholipid 
and protein components of the cell membrane, leading to lysis and release of the cell contents, 
while NaOH denatures proteins and DNA. The lysate is then neutralized under high salt 
conditions, causing denatured proteins, SDS and high molecular weight chromosomal DNA 
to co-precipitate and form insoluble complexes, while the plasmids, because they are closed 
circular molecules, renature and stay in solution [72]. In addition to neutralizing the lysate, 
the high salt concentration adjusts the DNA to adsorption onto the silica membrane that is 
now often used in plasmid extraction kits [72, 73]. Because mtDNA is also covalently closed 
circular molecules, bacterial plasmid isolation kits can be used to purify mtDNA. It should be 
noted, however, that nuclear DNA is prone to shearing during the lysis procedure because it 
consists of large linear molecules. In the protocol, mixing must thus be carried out carefully 
since nuclear DNA fragments are chemically indistinguishable from mtDNA under the 
conditions used. The two species will consequently not be separated on the silica membrane 
and will both elute under the same low-salt conditions [72]. 
The use of solid-phase reversible immobilization (SPRI) for purification of double-stranded 
PCR products was first described by Hawkins et al. [74]. They discovered that carboxyl-
coated paramagnetic
6
 beads could reversibly bind DNA under conditions of high polyethylene 
glycol (PEG) and salt. The size of the DNA fragments that bind to the beads depends on the 
PEG concentration: the lower the bead:DNA ratio, the larger the fragments that will bind. For 
kits that are commercially available today, the recommended ratio is usually 1.8 so that the 
beads will selectively bind DNA fragments of 100 base pairs and larger, while excess primers, 
nucleotides, salts, and enzymes are washed away [75]. But in the method for mtDNA 
                                                 
6
 Paramagnetic beads are magnetic only in a magnetic field. This prevents them from clumping together and 
falling out of solution. 
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enrichment that Quispe-Tintaya et al. designed, beads were added in a 0.4x proportion by 
volume in order to remove excess primers as well as the bulk of shared nuclear DNA. In this 
way, they were able to achieve more than 2000-fold enrichment for mtDNA when compared 
with total cellular DNA as demonstrated by real-time PCR [52]. 
2.5.1 Establishment and culture of skin fibroblasts 
Fibroblasts were established from a skin biopsy of patients 2and 3 under local anesthesia. The 
skin fibroblasts were cultured at 37°C and 5% CO2 in 75-cm
2
 tissue culture flasks containing 
10 mL of Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies) supplemented 
with 1 M HEPES buffer solution, Penicillin-Streptomycin, and 10% fetal bovine serum 
(FBS). After the cells had grown to confluence, the medium was removed and the culture 
surfaces of the 75-cm
2
 flasks were washed twice with 10 mL of Dulbecco’s Modified 
Phosphate-Buffered Saline (DPBS) (Life Technologies).  To allow cells to detach from the 
culture flask surface, 2 mL of 0.05% trypsin/EDTA were added to each flask. After 3-5 min 
of incubation at 37°C, the cell solution was placed in a 15 mL conical tube containing 10 mL 
DMEM, and 50 µL of the solution was used to count the cells with NucleoCounter NC-100 
(Chemometec) according to manufacturer’s instructions. The cell solutions were then 
centrifuged for 10 min at 400 x g. The pelleted cells were washed once with 1.5 mL DPBS 
and transferred to 2 mL micro centrifuge tubes. Approximately 10 million cells were used for 
each mtDNA extraction. In addition, 3 million cells were used to extract genomic DNA from 
each sample for control purposes.   
2.5.2 mtDNA and gDNA extraction 
The QIAprep Spin Miniprep Kit (Qiagen) was applied as the first step for mtDNA extraction 
and enrichment from the cell pellets. The procedure was performed according to 
manufacturer’s recommendations, and DNA was eluted in 80 µL of elution buffer that was 
pre-heated to 70°C. Optional LyseBlue reagent was used to avoid inefficient cell lysis and 
incomplete precipitation of SDS, nuclear DNA, and cell debris. Mixing during the lysis 
procedure was carried out by slow and gentle inversion of the tube to reduce shearing of 
nuclear DNA. The extracted DNA was quantified and assessed for purity on the NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific). In parallel, GenElute Mammalian 
Genomic DNA Miniprep Kit (Sigma) was used to extract genomic DNA (gDNA) from the 
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cell pellets of both samples. DNA was eluted in 200 µL of elution solution, and purity and 
quantity was measured with NanoDrop. 
2.5.3 Further purification and enrichment with AMPure 
Fractions of the mtDNA-enriched samples were further purified manually with Agencourt 
AMPure XP system (Beckman Coulter) using a DynaMag-96 Side Skirted magnet (Life 
Technologies). The magnetic beads were added in a 0.45x proportion by volume, collected on 
the magnetic stand, and washed twice with freshly prepared 70% ethanol. After air-drying the 
beads, the mtDNA was resuspended in 40 µL of 10 mM Tris-Cl, pH 8.5. For comparison 
purposes, the gDNA samples were likewise purified with the AMPure XP system and 
resuspended in 40 µL of Tris-Cl buffer. 
2.5.4 Relative quantification of mtDNA enrichment 
To measure the relative level of mtDNA enrichment obtained with this method we performed 
real-time qPCR using SYBR Green JumpStart Taq ReadyMix (Sigma) for detection of 
amplification. Two primer pairs were used, one specific for the mitochondrial gene 
tRNA
Leu(UUR)
, and the other specific for the nuclear gene β-2-microglobulin (β2M) [76] (Table 
8). The mitochondrial tRNA
Leu(UUR)
 gene region is rarely deleted and contains only a few 
single nucleotide polymorphisms, while β2M is a single copy nuclear gene and was used for 
normalization [37, 76]. The specificity of the primers was checked with In-Silico PCR 
(http://genome.ucsc.edu/cgi-bin/hgPcr). The real-time qPCR reaction (Table 9) was 
performed in triplicate for each reaction and fluorescent signal intensity of PCR products was 
recorded and analyzed on QuantStudio 12K Flex (Applied Biosystems) using QuantStudio 
12K Flex Software v1.2.2. Relative levels of mtDNA enrichment were calculated with the 
formula RQ=2
(-ΔΔCt) 
using the gDNA sample as reference and β2M as endogenous control.  
Name Sequence (5'- 3') 
Amplicon 
size (bp) Tm (°C) GC (%) 
tRNA F3212 CACCCAAGAACAGGGTTTGT 107 59.9 64.2 
tRNA R3319 TGGCCATGGGTATGTTGTTA 
 
59.7 45.0 
ß2M F594 TGCTGTCTCCATGTTTGATGTATCT 86 62.1 65.9 
ß2M R679 TCTCTGCTCCCCACCTCTAAGT  61.7 65.6 
Table 8 qPCR primer sequences. Melting temperatures were calculated by In-Silico PCR assuming 50 mM salt and 50 nM 
annealing oligo concentration. 
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Component  Volume (µL)   Stage Temperature Time 
H2O 2.0   Stage 1 50°C 2 min 
Fwd primer (5 µM) 1.0   
 
95°C 10 min 
Rev primer (5 µM) 1.0   Stage 2 95°C 15 sec 
2X SYBR Green ReadyMix 5.0   
 
60°C 1 min 
DNA (1.0 ng/µL) 1.0   Stage 3 95°C 15 sec 
Total 10.0   60°C 1 min 
    95°C 15 sec 
Table 9 qPCR reaction mixture and cycle parameters. The internal reference dye ROX was added to the SYBR Green 
mix for reaction normalization. Stage 3 of the qPCR reaction was for melting curve analysis.  Stage 2: 40 cycles. 
2.5.5 PCR amplification of mtDNA 
Fractions of the mtDNA enriched samples were subjected to 10 cycles of PCR amplification 
to check whether PCR improves the sequencing results as compared to using non-amplified 
mtDNA samples. By limiting the number of PCR cycles, the potential production of artifacts 
is also reduced. The mtDNA was amplified using a set of 9 overlapping primer pairs covering 
the whole mitochondrial genome (Table 11; Figure 8). These primers were validated and 
tested by Ramos et al. [51] to selectively amplify the mtDNA and avoid co-amplification of 
nDNA sequences of mitochondrial origin (NUMTs). Each of the 9 mtDNA fragments was 
amplified separately on a Veriti 96-Well Thermal Cycler (Applied Biosystems) using 
AmpliTaq Gold DNA Polymerase with Gold Buffer (Applied Biosystems). PCR reaction mix 
components for each primer pair and cycle parameters are shown in Table 10. The amplified 
PCR fragments were pooled together, purified with the AMPure XP system adding beads in a 
1.8x proportion by volume, and eluted in 25 µL Tris-Cl buffer. The mtDNA samples were 
then quantified using Qubit 2.0 Fluorometer (Life Technologies).     
 
Component  Volume (µL)   Stage Temperature Time 
H2O 16.4   Stage 1 96°C 5 min 
Primers (10 µM) 1.0   Stage 2 94°C 1 min 
10 mM dNTP 0.5     56°C 40 sec 
25 mM MgCl2 1.5     72°C 2.5 min 
AmpliTaq Gold (5U/µL) 0.1   Stage 3 72°C 5 min 
10X Gold Buffer 2.5   4°C ∞ 
mtDNA (~7 ng/µL) 3.0         
Total 25.0         
  
        
Table 10 PCR reaction mixture and cycle parameters used for amplification of the whole mtDNA. 
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Fragment Amplicon size  Name Sequence (5'-3') Primer length  Tm GC  (%) 
1 1822 1489F tagccatgcactactcaccaga 22 60.8 50 
  
151R ggatgaggcaggaatcaaagac 22 62.2 50 
2 1758 1648F ctgtatccgacatctggttcct 22 60.4 50 
  
1677R gtttagctcagagcggtcaagt 22 60.1 50 
3 2543 1404F acttaagggtcgaaggtggatt 22 60.2 45.5 
  
3947R tcgatgttgaagcctgagacta 22 60.0 45.5 
4 3005 3734F aagtcaccctagccatcattcta 23 59.2 43.5 
  
6739R gatatcatagctcagaccatacc 23 54.6 43.5 
5 2709 6511F ctgctggcatcactatactacta 23 54.2 43.5 
  
9220R gattggtgggtcattatgtgttg 23 61.3 53.5 
6 1738 8910F cttaccacaaggcacacctaca 22 60.1 50 
  
10648R ggcacaatattggctaagaggg 22 62.0 50 
7 1866 10360F gtctggcctatgagtgactaca 22 57.0 50 
  
12226R cagttcttgtgagctttctcgg 22 61.5 50 
8 1853 11977F ctccctctacatatttaccacaac 24 56.1 41.7 
  
13830R aagtcctaggaaagtgacagcga 23 61.6 47.8 
9 1872 13477F gcaggaatacctttcctcacag 22 60.1 50 
  
15349R gtgcaagaataggaggtggagt 22 59.6 50 
Table 11 Validated primers to amplify the complete mtDNA in nine overlapping fragments. Melting temperatures were 
calculated by In-Silico PCR assuming 50 mM salt and 50 nM annealing oligo concentration (from Ramos et al. [51]). 
 
 
Figure 8 Schematic representation of mtDNA. The nine overlapping fragments defined to PCR amplify the complete 
mtDNA genome are represented as well as the different gene regions in human mtDNA (from Ramos et al. [51]). 
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2.5.6 Massively parallel sequencing of mtDNA 
In total, five mtDNA enriched samples from patients 2 and 3 were sequenced by massively 
parallel sequencing (Table 12). Sample preparation method and sequencing platform were 
chosen in consultation with Gregor Duncan Gilfillan of the Norwegian Sequencing Centre 
(NSC). Individual libraries were constructed for each of the five samples by randomly 
shearing the mtDNA with a Covaris E220 ultrasonicator (Covaris) producing double-stranded 
fragments with an average size of 500bp. The sheared mtDNA was concentrated using 1.8 
volumes of AMPure XP beads (Beckman Coulter) according to manufacturer’s instructions 
and eluted in 33 µL 10 mM Tris. Preparation of the libraries was carried out using the 
MicroPlex Library Preparation kit (Diagenode) according to manufacturer’s 
recommendations. Maximum input volume of 10 µL (1-3 ng) was used for all samples (Table 
12). Indices were assigned to allow sequencing of all samples in one lane. The Microplex 
libraries were amplified by a total of 14 PCR cycles (4 cycles in step 4 and 10 cycles in step 5 
of Section 3 in the Microplex procedure, version 3). Sequencing was performed by NSC on 
an Illumina MiSeq using paired end 300bp V3 reagents according to manufacturer’s 
instructions. Image analysis and base calling were performed using Illumina’s RTA software 
version 1.18.54. Reads were filtered to remove those with low base call quality using 
Illumina’s default chastity criteria.       
Sample Patient mtDNA enrichment method 
Input volume 
(µL) 
mtDNA input (ng) 
1 2 MP + PCR 10 1.29 
2 
 
MP + AMP 10 0.96 
     
3 3 MP + PCR 10 3.12 
4 
 
MP + AMP 10 1.36 
5 
 
MP + AMP + PCR 10 2.42 
Table 12 mtDNA enriched samples and input amount for massively parallel sequencing. MP, miniprep; AMP, 
purification using 0.45x AMPure beads; PCR, 10 cycles of PCR amplification using nine overlapping primer pairs. 
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Reads that passed Illumina’s quality filter were aligned to the reference human genome 
(GRCh37/hg19) using Burrows-Wheeler Aligner tool (http://bwa.sourceforge.net/). PCR 
duplicates were marked with Picard tools (http://broadinstitute.github.io/picard/). Variant 
calling and filtering was performed using the Genome Analysis Toolkit (GATK) 
(https://www.broadinstitute.org/gatk/), and variants were annotated with SnpEff 
(http://snpeff.sourceforge.net/). 
2.6 Detection of mtDNA deletion in patient 3 muscle tissue 
A frozen muscle sample from patient 3 was sent to the Nijmegen Center for Mitochondrial 
Disorders (NCMD) for mitochondrial DNA analysis. From DNA isolated from the muscle 
sample the complete mtDNA was screened for mtDNA rearrangements using Long Template 
PCR. This revealed the almost homoplasmic deletion m.6211_8681del in the patient’s muscle 
tissue.  
2.6.1 Detection and verification of mtDNA deletion in skin tissue 
To determine whether the same mtDNA deletion (m.6211_8681del) was present in the 
patient’s skin tissue, we performed PCR on genomic DNA isolated from skin fibroblasts 
using a set of designed primers flanking the deletion breakpoints (Table 13).  PCR reaction 
mixture and cycling conditions were the same as in 2.5.5 with the exception that 50-60 ng of 
genomic DNA was used as template. In addition to genomic DNA from fibroblasts, we also 
performed PCR on genomic DNA isolated from the patient’s blood. DNA from a commercial 
fibroblast cell line was used as control. 
Name Sequence (5'- 3') Tm (°C) GC (%) 
m6073For TCGTCACAGCCCATGCATTT 64.9 50.0 
m9065Rev GCTAGGGTGGCGCTTCCAAT 65.8 60.0 
Table 13 PCR primers used for detection of mtDNA deletion. The primers were designed using Primer3 and checked for 
sequence specificity using In-Silico PCR. Universal M13 tales (not shown) were also added for later Sanger sequencing. The 
amplicon size is 2993bp with the deleted region included and 579bp without it. With the M13 tales included, the amplicon 
size is 3029bp and 559bp, respectively. 
 
PCR amplification resulted in two distinct bands for the patient samples and one band for the 
control sample. To verify that these bands corresponded to the full-length and deleted 
fragments, we Sanger sequenced the amplified PCR fragments. DNA was first extracted from 
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the agarose gel and purified using QIAquick Gel Extraction Kit (QIAGEN) and then Sanger 
sequenced following exactly the same procedure as in 2.3-2.3.3. The raw sequence data 
generated was finally analyzed using Sequencing Analysis 5.1. 
2.6.2 Quantification of heteroplasmy levels of mtDNA deletion 
The mtDNA deletion m.6211-8681del was verified by Sanger sequencing in both muscle and 
blood. The heteroplasmy levels of the deletion in the two tissues were quantified with qPCR 
using two primer pairs (Table 14). The first pair was designed to flank the deleted region. The 
short extension time used in this qPCR experiment (1 min) means that amplification will take 
place only if the deletion is present. This is because the amplicon size would be 2561bp with 
the deleted fragment included, which is too much to be amplified during the short extension 
time. On the other hand, the amplicon size is only 91bp without the deleted fragment and 
amplification therefore readily takes place. This primer pair was thus used to detect only those 
mtDNA molecules that contain the deletion. The second primer pair was targeted to the 
tRNA
Leu(UUR)
 gene region, which is not deleted in the patient and which is not a common site 
for single nucleotide polymorphisms. In addition, this region does not harbor any of the point 
mutations detected by massively parallel sequencing. The tRNA primer pair was therefore 
designed to detect all mtDNA molecules regardless of whether the deletion was present or 
not. When designing the primers, amplicon size and melting temperatures were adjusted as 
much as possible and sequence specificity was checked with both BLAT and In-Silico PCR. 
The PCR conditions and amplification program were the same as in 2.5.4 except that 2 ng of 
gDNA was used.  
Name Sequence (5'- 3') 
Amplicon 
size (bp) Tm (°C) GC (%) 
mDEL F6170 CCCCGATATGGCGTTTCC 91 63.5 61.1 
mDEL R8730 TCAGGTTCGTCCTTTAGTGTTGTG  62.6 45.8 
tRNA F3244 GCCCGGTAATCGCATAAAACTTA 98 63.2 43.5 
tRNA R3341 GGTACAATGAGGAGTAGGAGGTTGG  63.3 52.0 
Table 14 Primers used for deletion quantification with qPCR.  
We also performed a primer efficiency test for more accurate relative quantification 
measurements. The test consisted of five points and was run in triplicates using 16 ng as 
starting quantity and 1:2 as serial factor. Genomic DNA extracted from patient 3 fibroblasts 
was used as template.  
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3 Results 
3.1 Whole exome sequencing and filtering of genetic variants 
Whole exome sequencing (WES) of DNA from the three families was performed as described 
in 2.2-2.2.2. Analysis and filtering of called variants (see 2.2.3) resulted in 25 potentially 
pathogenic variants in patient 1 (Table 15), 19 variants in patient 2 (Supp. Table S1), and 21 
variants in patient 3 (Supp. Table S2). Literature searches using OMIM and PubMed were 
carried out to identify causative links between the detected variants and the clinical 
manifestations of the patients. Based on these searches, the homozygous SURF1 variant 
c.106+1G>C was concluded to be the best candidate in patient 1. None of the putative 
variants found in patients 2 and 3 were considered to be causative of the clinical phenotypes. 
Table 15 Putative pathogenic variants in patient 1 detected by whole exome sequencing and retained after filtering.  
The SURF1 variant is marked in red. 
Gene name Chr:pos Ref Alt 
Amino acid 
change 
  Effect Depth 
TENM1 X:123519883 C T R1900H Non-synonymous 86 
NOS2 17:26093598 A C H689Q Non-synonymous 109 
TCHH 1:152080993 C G R1567T Non-synonymous 93 
GTF3C5 9:135930371 G C S278T Non-synonymous 86 
PDCD11 10:105202091 G T R1610L Non-synonymous 42 
CEBPD 8:48650242 C A *134L Stop lost 10 
UBTF 17:42289077 T G N278T Non-synonymous 56 
SCN4A 17:62018451 C T A1731T Non-synonymous 101 
FCN1 9:137804452 G A R148W Non-synonymous 46 
FRAS1 4:79188076 T G L259R Non-synonymous 91 
ARIH1 15:72767034 TGAG T E19- In-frame codon deletion 50 
SURF1 9:136223123 G C c.106+1 Splice site substitution 11 
SMTN 22:31486854 C A A301D Non-synonymous 103 
PROM2 2:95941792 G A G137R Non-synonymous 97 
WRAP53 17:7604812 T C I223T Non-synonymous 104 
LAMC3 9:133920949 C T P474L Non-synonymous 89 
PCDHA12 5:140256415 C T P453L Non-synonymous 38 
TRIM45 1:117659283 C T G379E Non-synonymous 32 
BMX X:15548115 T G S302A Non-synonymous 47 
SLC27A3 1:153752324 C G T141S Non-synonymous 99 
PCYT1B X:24597545 C G G181A Non-synonymous 37 
RAB25 1:156035733 G C K25N Non-synonymous 58 
SRRM2 16:2820684 C T P220S Non-synonymous 70 
CCDC120 X:48926120 C T R638C Non-synonymous 63 
GABRE X:151123944 C T A345T Non-synonymous 42 
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3.2 Verification of c.106+1G>C variant in SURF1 
SURF1 is one of at least six nuclear genes controlling the assembly of the 13 subunits 
constituting complex IV (cytochrome c oxidase (COX)) of the respiratory chain. Mutations in 
SURF1 are primarily associated with Leigh and Leigh-like syndrome [77]. The WES results 
showed a low depth of coverage (11x) of the SURF1 variant position compared to the other 
variants detected (Table 15). However, Sanger sequencing confirmed that the patient was 
homozygous for the variant while the parents were heterozygous (Figure 9). 
 
Figure 9 Confirmation by Sanger sequencing of the c.106+1G>C variant in SURF1. The variant was confirmed in both 
forward and reverse directions. PF, patient forward; FF, father forward; MF, mother forward; PR, patient reverse; FR, father 
reverse; MR, mother reverse.  
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3.2.1 Skipping of exon 2 in SURF1 
The c.106+1G>C variant is located in the donor splice site of intron 2 and was predicted by 
Alamut Visual 2.6.1 (Interactive Biosoftware) to cause a skip of exon 2. Since exon 2 is 52bp, 
skipping results in a shift of the reading frame, and nonsense-mediated decay (NMD) of the 
transcript is likely to result [78]. This variant has previously been reported in a Pakistani 
patient with Leigh syndrome [57], but the authors did not document the skipping of exon 2. 
Using primers targeted to exon 1 and 5 of the transcript (Supp. Figure S1), PCR amplification 
of cDNA gave only one fragment of approximately 400bp in the patient, while this same 
fragment and one larger fragment were detected in both parents (Figure 10). The expected 
size of the amplicon was 422bp if exon 2 was retained and 370bp if it was skipped. Our PCR 
result was therefore in agreement with the prediction that the c.106+1G>C splice site 
mutation results in skipping of exon 2. Furthermore, the result supported the finding that the 
patient was homozygous for the mutation while the parents were heterozygous.   
 
Figure 10 Exon 2 skipping in SURF1. The PCR results support the prediction that the splice site variant leads to a skip of 
exon 2. P, patient; F, father; M, mother.  
 
To assess if the genetic variant causes exon 2 skipping, the fragments obtained with PCR 
were Sanger sequenced (see 2.4.1-2.4.2). Sanger sequencing confirmed that exon 2 was 
absent in the fragment amplified from patient DNA only, as exon 3 was continuous with exon 
1 in the patient, while it was continuous with exon 2 in both parents (Figure 11).  
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Figure 11 Verification of exon 2 skipping in patient 1. a) The electropherograms show that exon 3 (underlined in black) is 
continuous with exon 1 (underlined in red) in the patient, while it is continuous with exon 2 (underlined in blue) in both 
parents. The sequencing data shown is for the reverse strand. b) Alignment of cDNA sequence from patient (top) and parents 
(middle) to the human reference sequence (GRCh38 assembly) shows that exon 2 is absent in patient DNA but retained in 
parental DNA. In the reference sequence, exons 3, 2, and 1 are shown in black, blue, and red, respectively. The sequence data 
shown is for the reverse strand. P, patient; F, father; M, mother. 
 
3.3 Sequencing the mitochondrial genome 
Since we could not detect any potentially pathogenic variants with whole exome sequencing 
in patients 2 and 3, we sought to sequence the mitochondrial genome to search for pathogenic 
mtDNA point mutations or large deletions that could explain the clinical manifestations of 
these two patients. In order to avoid the generation of artifacts associated with PCR 
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amplification, we enriched the samples for mtDNA using the method developed by Quispe-
Tintaya et al. [52]. In addition, we carefully chose a DNA library preparation protocol and 
high-throughput sequencing platform that would result in deep and even coverage of the 
entire mtDNA (see 2.5-2.5.6). Deep coverage allows detection and quantification of low-level 
heteroplasmic point mutations that may not be detected by other sequencing methods like 
Sanger sequencing [79]. 
3.3.1 Relative quantification of mtDNA enrichment 
Enrichment of the samples for mtDNA was carried out in two stages using QIAGEN 
Miniprep Kit and AMPure purification beads. Relative mtDNA enrichment levels were 
measured by qPCR using two primer sets (see 2.5.4: Table 8; Figure 12a). The tRNA primers 
were specific to an mtDNA region that is rarely deleted and contains only a few rare single 
nucleotide polymorphisms (mtSNP), while the β2M primers were specific to a single copy 
nuclear gene. Relative enrichment (RQ) was calculated by the formula RQ = 2
(-ΔΔCt)
, in which 
the total cellular DNA sample was used as reference and the β2M target as endogenous 
control. In other words, the difference between the Ct values of tRNA and β2M in the mtDNA 
enriched samples was normalized to the difference between the Ct values of tRNA and β2M 
in the total cellular DNA sample. The qPCR measurement indicated a 280 and 730 fold 
enrichment after AMPure purification of the mtDNA samples for patients 2 and 3, 
respectively (Figure 12b). Although the relative enrichment was apparently higher in patient 
3, the actual number of mtDNA copies in the enriched samples themselves was 9 times 
greater in patient 2 than in patient 3, as indicated by the difference in Ct values (ΔCt) between 
tRNA and β2M in the “miniprep and AMPure” samples (Figure 12a; Table 16). The reason 
for this is that the ΔCt value in the total cellular DNA sample, to which the enriched samples 
were normalized, was much higher in patient 2 than it was in patient 3 (Figure 12a). The 
relative enrichment value is therefore not a measurement of the actual mtDNA copy number 
in the sample.    
42 
 
 
Figure 12 Relative quantification of mtDNA enrichment. a) Mean Ct values obtained after qPCR quantification of 
mitochondrial and nuclear DNA. tRNA is the mtDNA target, while β2M is the nuclear DNA target. Note that the ΔCt value 
for the AMPure sample is much higher in patient 2 than it is in patient 3, but the same is the ΔCt value for the total cellular 
DNA sample. That is why the mtDNA fold enrichment was greater for patient 3. b) Relative enrichment of mtDNA over 
nuclear DNA using miniprep kit alone and miniprep kit plus AMPure. In both patients, AMPure significantly increased the 
mtDNA enrichment levels. 
3.3.2 Massively parallel deep sequencing of mtDNA 
In total, five mtDNA enriched samples were massively parallel sequenced; two samples from 
patient 2 and three samples from patient 3 (see 2.5.6: Table 12). The samples were prepared 
using the MicroPlex Library Preparation Kit (Diagenode), which allows for as little as 50 
picogram input of fragmented dsDNA. Paired-end sequencing was then performed on an 
Illumina MiSeq platform. Paired-end sequencing enables both ends of the DNA fragments to 
be sequenced. Since the distance between each paired read is known, alignment algorithms 
can use this information to map reads over regions containing repetitive sequences and to 
detect structural rearrangements. Because paired-end reads are more likely to align correctly 
to a reference, the data quality as well as the overall coverage level greatly improve [80]. 
Improved depth of coverage is one of the crucial factors in the detection of low-frequency 
heteroplasmic mtDNA variants [42]. 
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As Figure 13 shows, a depth of coverage ranging from 10,000 to 130,000 per base position 
was achieved for all the samples, although the coverage was not uniform in all cases. Only 
with the two PCR free samples did we achieve uniform coverage across the entire 
mitochondrial genome. The depth of coverage in these two samples was approximately 
60,000 for patient 2 and 40,000 for patient 3 (Figure 13 A and B). This difference in coverage 
was probably due to the fact that the patient 2 sample had an mtDNA:nDNA copy number 
ratio that was 9 times greater than the patient 3 sample had (Table 16). Therefore, neither 
input amount nor relative mtDNA enrichment was predictive of the coverage level to be 
achieved by massively parallel sequencing of mtDNA. Both these values were greater in the 
sample from patient 3, but that was not reflected in the coverage results (Table 16).  
On the other hand, the three samples that were enriched for mtDNA by PCR resulted in 
uneven coverage of the mtDNA genome (Figure 13 C-E). Moreover, the coverage pattern for 
each sample clearly mirrored the positions of the nine overlapping PCR fragments produced 
during amplification. The exception was fragments 3, 4 and 5, which had reduced coverage in 
all three samples (Figure 13 C-E). These three fragments were also the largest fragments and 
were probably amplified less efficiently do to the relatively short extension time that was used 
(2.5 min) (see 2.5.5: Table 11). The first 1000bp of the mtDNA genome had poor sequence 
coverage regardless of the enrichment method (Figure 13 A-E). The reason for this is unclear, 
but this region is part of the D-loop, which is a highly polymorphic non-coding mtDNA 
region. The more polymorphic a DNA region is, the less likely it is that it will align correctly 
to the reference genome, leading to apparently reduced coverage of that region [81]. Similar 
low coverage of this region has been observed before [82]. 
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Figure 13 Depth of coverage achieved with and without the use of PCR for mtDNA enrichment. Samples presented in 
C, D, and E were enriched by 10 cycles of PCR using nine overlapping primer pairs. In all of these samples, deep sequencing 
resulted in an uneven coverage across the entire mitochondrial genome, ranging from 10,000 to as high as 130,000 (indicated 
in the Y-axis). In contrast, the coverage was uniform throughout the mtDNA genome when PCR was not used for target 
enrichment. The horizontal lines numbered from 1 to 9 represent the nine overlapping fragments amplified by PCR (See 
Figure 8). As can be seen, the coverage pattern in each of the three PCR samples correlates very closely with the distribution 
of the fragments. The colored vertical lines indicate the positions of the single nucleotide variants detected. P2, Patient 2; P3, 
Patient 3; MP, Miniprep; AMP, 0.45xAMPure; PCR, 10 cycles of PCR amplification. 
 
 
 
Table 16 Relationship between depth of coverage and mtDNA:nDNA copy number ratio in “miniprep and AMPure” 
samples. The mtDNA:nDNA copy number ratio was calculated using the formula 2ΔCt, where ΔCt is the difference in Ct 
values between mtDNA target (tRNA) and the nDNA target (β2M). Note that relative enrichment levels and DNA input 
amount do not correlate with the achieved coverage. 
 
 
Patient 2 Patient 3
mtDNA:nDNA 147 464 16 498
Relative enrichment 276 729
Input (ng) 0.96 1.36
Coverage ~60 000 ~40 000
Miniprep and AMPure
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3.3.3 Summary of sequencing results 
PCR amplification during target enrichment for massively parallel sequencing complicates 
genotyping because PCR introduces sequence errors and duplicates template molecules [83]. 
Duplicates are defined as reads with the same start position and orientation [84]. Since they 
are identical copies of template molecules, they can strongly inflate and distort the read 
coverage data, making it necessary to remove them before carrying out coverage calculations 
in the alignment [85]. The percentage of duplicate reads was consistently higher in the PCR 
enriched samples than in the samples not amplified by PCR. Removing the duplicates 
therefore resulted in a significantly lower number of unique reads in the PCR amplified 
samples (Table 17). However, when considering the percentage of unique bases that aligned 
to the mtDNA genome, the number was significantly higher in two of the three PCR enriched 
samples. One advantage of PCR enrichment over PCR free enrichment seems therefore to be 
that the former is more effective in that it can achieve high target coverage with fewer reads. 
This advantage is also reflected in the fold enrichment, which is the fold by which the target 
region has been amplified above the reference genome (Table 17). 
 
Sample 
Total 
reads 
Unique 
reads 
% unique 
reads  
Unique 
bases 
aligned to 
mtDNA 
% unique 
bases 
aligned to 
mtDNA 
Fold 
enrichment 
P2: MP+PCR 11495296 4564993 39,7 856874111 87,7 166012 
P2: MP+AMP 11106524 8873390 79,9 955347809 50,8 96280 
P3: MP+PCR 9508602 5897473 62,0 581856061 49,5 93640 
P3: MP+AMP 9076904 8390339 92,4 612600347 33,8 64028 
P3: MP+AMP+PCR 9000376 3846280 42,7 731523477 92,0 174204 
 
Table 17 Summary of sequencing results. Unique reads are reads not marked as PCR duplicates. MP, Miniprep; AMP, 
0.45xAMPure; PCR, 10 cycles of PCR amplification 
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3.3.4 Quality assessment of sequencing data 
Quality assessment of the raw sequence data from the mtDNA enriched samples was carried 
out with FastQC quality control tool (http://.bioinformatics.babraham.ac.uk/projects/fastqc), 
which runs a set of quality checks producing a report that allows for quick assessment of the 
overall quality of the run. One of these checks calculates the average Phred quality score per 
sequence read, and gives an overview of the quality score distribution over all sequences in 
the sample. The Phred score (Q) is logarithmically linked to the base calling error 
probabilities (P): Q =  – 10 x log P [86]. For example, if Q is 30, this is equivalent to the 
probability of an incorrect base call being 1 in 1000. The most commonly used cutoff, 
however, is a Phred quality score of Q = 20 [87], meaning that the probability of incorrect 
base calling is 1 in 100. In each of the five mtDNA enriched samples, the majority of reads 
(>95%) had an average quality score above 20 (Figure 14; Supp. Figure S2; Supp. Figure S3). 
Interestingly, there were no marked differences in average quality per read between the PCR 
enriched samples and the PCR free samples.  
 
Figure 14 Distribution of average quality score per sequence. Ideally, only one peak should be seen to the far right, 
indicating that all sequences have the same average Phred score above 30. But even though our results were short of the 
ideal, the majority of sequences (>95%) had an average score above 20, which is the generally accepted cutoff. Only the 
results from one sample are shown here, the remaining samples are shown in Supplementary Figures S2 and S3. P3, patient 
3; MP, miniprep; AMP, AMPure.  
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3.4 Detection of mtDNA deletion in patient 3 
Mitochondrial DNA analysis of muscle tissue from patient 3 was carried out at the Nijmegen 
Center for Mitochondrial disorders (NCMD), which identified the almost homoplasmic 
deletion m.6211_8681del (Figure 15). To assess if the same deletion was present in cells from 
the patient’s blood and skin as well, the genomic region containing this deletion was PCR 
amplified using a set of primers flanking the deletion breakpoints (see 2.6.1: Table 13). PCR 
amplification resulted in two fragments in DNA isolated from the patient’s blood and skin 
tissue samples, while PCR in the control sample only produced one fragment (Figure 16). The 
theoretical size of PCR fragments from mtDNA molecules without the deletion is 3029bp, 
corresponding very well with the large fragment produced by PCR in both patient and control 
samples. The additional small PCR fragment produced in the patient samples indicated that 
the deletion was also present in the patient’s blood and skin mtDNA.  
 
Figure 15 The mtDNA deletion detected in patient 3. The deletion m.6211_8681del is 2469bp and spans the genes COI, 
TRND, COII, TRNK, ATPase8 and part of ATPase6 (adapted from Zeviani et al. [56]).  
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Figure 16 Detection of mtDNA deletion in blood and skin tissues from patient 3. The two PCR bands seen in the patient 
samples indicate that the mtDNA deletion was present in the patient’s blood and skin in addition to muscle. The control 
sample only resulted in one PCR band corresponding to the full-length amplicon. The reason why the biggest bands in the 
patient samples is weaker than the corresponding band in the control sample, is probably that the DNA polymerase used in 
this PCR run is more efficient for smaller amplicons, which therefore out-compete the bigger ones. We also see that the small 
band in P3 FBL has stronger intensity than in PR BLD. This indicates that the heteroplasmy level of the deletion is greater in 
the patient’s skin tissue than in blood. P3, patient 3; FBL, fibroblast; BLD, blood.       
 
The small PCR fragments from the two patient samples were excised from the gel, purified, 
and Sanger sequenced to determine the sequence of the mtDNA region containing the 
deletion in the patient’s fibroblast and blood DNA (see 2.6.1). As Figure 17 shows, the 
deletion was detected in both tissues and was verified in both forward and reverse directions, 
clearly indicating that the mtDNA region 6211-8681 was deleted in the patient’s fibroblast 
and blood tissues.  
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Figure 17 Verification of mtDNA deletion in patient 3 by Sanger sequencing. a) Bases underlined in blue indicate the 
mtDNA sequence upstream of the deleted region, while the bases underlined in read indicate the mtDNA sequence 
downstream of the deletion. All sequences are shown in the 5’-3’ direction. b) Alignment of patient mtDNA sequence (blood 
and skin mtDNA) to the human reference sequence (GRCh38) in forward (top) and reverse (bottom) directions. The 
m.6211_8681del deletion is marked in red. Only the ends of the deletion are shown. FBL, fibroblasts; BLD, blood. 
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3.4.1 Relative quantification of heteroplasmy levels 
Relative heteroplasmy levels of the verified mtDNA deletion were measured by qPCR using 
two different primer pairs; one flanking the deletion breakpoints (mDEL) and the other 
targeting a conserved mtDNA region outside the deletion (tRNA) (see 2.6.2: Table 14). Mean 
Ct values for the qPCR experiments are shown in Table 18. Melt curve analysis showed a 
single peak for all samples, indicating that both primer pairs produced a single, specific 
product (Figure 18). Relative heteroplasmy levels were calculated using the formula:  
2([Ct(tRNA)∙E(tRNA)] - [Ct(mDEL)∙E(mDEL)]) 
in which “Ct” is the mean Ct value for each primer pair and “E” is the PCR primer efficiency 
as determined by running a primer efficiency test, which was included to increase the 
accuracy of the calculation (see 2.6.2; Figure 19). Relative heteroplasmy levels of the mtDNA 
deletion in the patient’s skin and blood were calculated using tRNA as reference and a PCR 
efficiency of 73.879% for tRNA and 73.056% for mDEL (Figure 19). Plotting these values 
into the formula, the relative heteroplasmy level of the mtDNA deletion was determined to be 
4.6% in the patient’s skin tissue and 2.9% in the patient’s blood (Table 18).   
 
 
Table 18 Mean Ct values and relative quantification of mtDNA deletion heteroplasmy levels in skin and blood. The 
tRNA primer pair was targeted to a conserved region outside the mtDNA deletion to detect all mtDNA molecules. The 
mDEL primers were design to flank the deletion breakpoints in order to detect only those mtDNA molecules containing the 
deletion. The Ct value for mDEL in the control sample could not be determined for any of the wells in the triplicate, 
indicating that the deletion was not present at all in the control mtDNA. P3, patient 3; FBL, fibroblasts. 
 
tRNA mDEL
P3 FBL 18,22 24,51
P3 Blood 19,16 26,39
Control 17,82 Undetermined
tRNA mDEL
P3 FBL 1 0.0459
P3 Blood 1 0.0286
Mean Ct values
Sample
Relative quantification
Sample
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Figure 18 Melt curve analysis. The melting curves show that the qPCR run produced only one product in all samples, 
indicating that the primers were specific for the targeted region. P3, patient 3; BLD, blood tissue; FBL, skin fibroblasts. 
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Figure 19 Primer efficiency test. The efficiency of the tRNA and mDEL primers was evaluated by performing a 5-fold 
dilution series experiment. The slope of the standard curve indicates PCR efficiency, which is calculated by the formula E = 
10(-1/slope). A slope value of -3.322 would give E = 2, which means exact doubling for each cycle and therefore 100% 
efficiency. The R2 value (correlation coefficient) is a measure of the closeness of fit between the standard curve and the 
individual Ct values of the standard reaction. A value of 1.00 indicates a perfect fit. An R2 value >0.99 is desirable. 
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3.5 mtDNA point mutations detected by MPS 
Massively parallel sequencing of mtDNA from fibroblasts detected 11 single nucleotide 
variants (SNVs) in patient 2 (Table 19) and 43 single nucleotide variants in patient 3 (Supp. 
Table S3). Since the m.6211_8681del deletion detected in patient 3 most likely is the disease-
causing variant, we did not analyze any further the mtDNA SNVs identified in this patient. Of 
the 11 genetic variants found in patient 2, only three affected protein coding regions, while 
the rest affected non-coding tRNAs, rRNAs, or the D-loop (Table 19). The depth of coverage 
achieved for these 11 positions using the non-PCR sample ranged from 26,000 to 60,000. 
With one exception, all the single nucleotide variants detected in this patient were present in a 
nearly homoplasmic state. The one exception was the D-loop mutation m.310T>C, which had 
a heteroplasmy level of 87%. Furthermore, approximately 65% of the mtDNA molecules had 
a T>TC insertion in this very same position (m.310T>TC).  
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Table 19 Mitochondrial DNA single nucleotide variants detected in patient 2 by massively parallel sequencing of fibroblast derived mtDNA.  With the exception of the m.310T>C 
variant, all point mutations were present in an almost homoplasmic state as seen by the read count and percentage values. The m.310 position had two heteroplasmic variants: the m.310T>C 
variant, which was present in 12% of mtDNA molecules, and the m.310T>TC insertion variant, which was present in ~66% of mtDNA molecules. 
     Nucleotide count 
Position Gene name 
Nucleotide 
change 
Amino acid 
change 
Total count A (%) C (%) G (%) T (%) Del Ins 
263 MT-DLOOP A>G non-coding 43283 271 (0.63) 171 (0.40) 42649 (98.54) 192 (0.44) 1 1 
310 MT-DLOOP T>C non-coding 26580 313 (1.18) 23059 (86.75) 36 (0.14) 3172 (11.93) 28 17416 (T>TC) 
456 MT-DLOOP C>T non-coding 34915 166 (0.48) 362 (1.04) 295 (0.84) 34092 (97.64) 25 1 
750 MT-RNR1 A>G non-coding 58715 334 (0.57) 100 (0.17) 58073 (99.91) 208 (0.35) 8 2 
1438 MT-RNR1 A>G non-coding 55839 247 (0.44) 37 (0.07) 55426 (99.26) 129 (0.23) 4 0 
4336 MT-TQ T>C non-coding 58019 176 (0.30) 57580 (99.24) 48 (0.08) 215 (0.37) 2 2 
4769 MT-ND2 A>G syn:M-M 52410 271 (0.52) 60 (0.11) 51816 (98.87) 263 (0.50) 4 1 
5839 MT-TY C>T non-coding 59214 139 (0.23) 106 (0.18) 132 (0.22) 58837 (99.36) 2 0 
8860 MT-ATP6 A>G non-syn:T-A 48111 236 (0.49) 183 (0.38) 47495 (98.97) 197 (0.41) 4 0 
15326 MT-CYB A>G non-syn:T-A 57310 266 (0.46) 135 (0.24) 56722 (98.97) 187 (0.33) 0 1 
16304 MT-DLOOP T>C non-coding 60184 277 (0.46) 59589 (99.01) 52 (0.09) 266 (0.44) 8 2 
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4 Discussion 
The great majority of respiratory chain subunits, translation machinery components, and 
almost all of the factors involved in mtDNA replication, transcription, translation, and repair 
are encoded by the nuclear genome [37]. In addition, nuclear DNA mutations account for 
more than 90% of all mitochondrial disorders in children [88]. For these reasons, analysis of 
the nuclear genome was the logical first step in the search for disease-causing variants in the 
three patients in this study.  
4.1 Genetic variants identified by whole exome sequencing 
Whole exome sequencing of DNA isolated from blood from the three patients and filtering of 
the called variants (see 2.1-2.2) resulted in the identification of 25 potentially pathogenic 
variants in patient 1 (Table 15), 19 variants in patient 2 (Supp. Table S1), and 21 variants in 
patient 3 (Supp. Table S2). To assess if any of these variants were likely to be causative of the 
clinical phenotypes of the patients, literature searches using OMIM and PubMed databases 
were carried out to identify potentially causal links between the genetic variants and the 
clinical phenotypes. Genes and genetic variants previously reported in these databases and 
implied in mitochondrial disease were specifically looked for. In addition, the mutation 
analysis software Alamut Visual 2.6.1 (Interactive Biosoftware) was used to assess the 
pathogenicity of the detected variants based on evolutionary conservation and molecular 
consequences of the mutations. Based on these assessments, the homozygous SURF1 variant 
c.106+1G>C was concluded to be the best candidate for further analysis in patient 1. None of 
the putative variants identified in patients 2 and 3 were considered to be good candidates for 
further analysis. 
4.2 SURF1 variant causes Leigh syndrome 
The c.106+1G>C variant, predicted by Alamut Visual 2.6.1 to cause skipping of exon 2, was 
verified in the patient by Sanger sequencing (see 2.3-2.3.3). The same homozygous variant 
has previously been reported in a Pakistani individual with Leigh syndrome (LS); however, 
the authors did not show the consequences of the mutation [57]. In the current work, skipping 
of exon 2 was demonstrated by PCR and Sanger sequencing (see 2.4-2.4.2).  
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The nuclear gene most frequently mutated in Leigh syndrome is SURF1 [77]. To date, more 
than 70 mutations in SURF1 have been reported in patients with LS [57]. The gene encodes 
the 300 amino acid mitochondrial protein SURF1, which is located in the mitochondrial inner 
membrane [89]. SURF1 contains a central part and two transmembrane domains, one in the 
N-terminus and the other in the C-terminus, that are thought to be essential for the protein 
function (Figure 20) [90]. Although SURF1 is known to be necessary for the assembly and 
maintenance of cytochrome c oxidase (COX; complex IV of the respiratory chain), its exact 
physiological function is still not fully understood [91]. Truncating mutations in the central 
part and both transmembrane domains result in an unstable protein that does not rescue COX 
activity in SURF1-deficient cell lines [89]. 
 
Figure 20 Schematic model of SURF1. The central part and the two transmembrane domains in the N- and C-termini of 
SURF1 are shown. SURF1 is believed to bind heme a (shown in middle) and incorporate it into COX subunit I as part of its 
role in COX assembly (from Hannappel et al. [91]). 
 
The majority of the 74 different LS-associated SURF1 mutations reported so far are splice 
site, nonsense, and frameshift mutations that may lead to nonsense-mediated decay (NMD) of 
the transcript (Supp. Table S4). Exon 2 of SURF1 is 52bp, and skipping of this exon results in 
frameshift early in the transcript, which may render the remaining protein non-functional even 
if the transcript is not targeted for NMD. This, and the fact that SURF1 c.106+1G>C has been 
reported in a patient with similar clinical manifestations as our patient, lead us to conclude 
that this mutation is likely the cause of disease in patient 1. 
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4.3 Mitochondrial DNA analysis by massively parallel sequencing  
Because none of the genetic variants identified by whole exome sequencing in patients 2 and 
3 were considered likely to be causative of the clinical phenotypes, the mitochondrial 
genomes of the two patients were analyzed by massively parallel sequencing. Fibroblasts 
from the patients were cultured and the mtDNA isolation protocol designed by Quispe-
Tintaya et al. was used to prepare mtDNA enriched samples (see 2.5-2.5.3). A fraction of 
each mtDNA sample was then subjected to direct massively parallel sequencing without prior 
amplification by PCR, while another fraction of each sample was first amplified by 10 cycles 
of PCR using 9 overlapping primer pairs covering the whole mtDNA genome (see 2.5.5-
2.5.6). Massively parallel sequencing resulted in deep coverage (10,000-130,000) of the entire 
mtDNA genome in all samples; however, the coverage was uniform only in the samples that 
were not PCR amplified prior to sequencing (see 3.3.2). In addition, massively parallel 
sequencing identified 11 single nucleotide variants in patient 2 and 43 variants in patient 3 
(see 3.5). 
4.3.1 Low-level heteroplasmy detection 
Although the mitochondrial genome remains one of the most widely studied DNA segments 
in humans [43], the several unique features of mitochondrial genetics still pose many 
challenges for the complete and accurate characterization of mtDNA genomes by 
conventional sequencing technologies [92]. Three challenges are of particular significance: 
the presence of thousands of copies of mtDNA in each human cell; the need for mtDNA 
enrichment prior to sequencing; and the presence of mtDNA sequences in the human nuclear 
genome. 
The first of these challenges is the presence of multiple mtDNA copies in each nucleated 
human cell, leaving open the possibility that all copies are not identical. Originally, 
heteroplasmy was believed to be quite rare in healthy individuals [93, 94]. However, recent 
work has shown that very low-level (>0.2%) heteroplasmic variance is universally present in 
healthy people [42]. Although heteroplasmic mtDNA mutations usually need to be present in 
at least 70-90% of mtDNA molecules in the relevant tissue to cause observable phenotypes 
[43], even mutations present at low levels in a female may result in an affected offspring 
because of the germ-line bottleneck in mtDNA segregation [95]. Therefore, sensitive 
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detection and accurate quantification of heteroplasmic pathogenic changes is of great 
importance in genetic counselling.  
The small size of the human mitochondrial genome and the resulting high coverage for each 
nucleotide position generated by massively parallel sequencing allow for the detection of low-
level mtDNA heteroplasmy. The mean coverage achieved in our study (>40,000) was much 
higher than what is typically seen in similar mtDNA sequencing studies [42, 43, 96-99] and 
should in principle allow us to detect very low heteroplasmy levels. However, the relatively 
high sequence error rate associated with massively parallel sequencing technologies can lead 
to false positives, meaning that sequencing errors may falsely be considered to be 
heteroplasmies [43]. There is therefore a need to establish a critical threshold by which 
background sequencing noise can be weeded out.  
In the present work, massively parallel sequencing detected four alleles in each position in the 
mtDNA. Moreover, one allele was typically overrepresented, while the three other alleles 
were present in only ~0.5% of mtDNA molecules (Table 19). Since it is unlikely that every 
position should harbor three low-frequency alleles and one high-frequency allele, the low-
frequency alleles most probably represent background noise generated by the sequencing 
process. This means that the critical threshold value for background noise in our experiments 
was most likely below 1%, meaning that all alleles with a frequency less than 1% can be 
discarded. This cut-off value is also in agreement with earlier studies [92, 97]. However, the 
exact detection threshold needs to be determined experimentally before any firm conclusion 
can be arrived at. One general method that could be applied to estimate the level of 
background noise experimentally is to use external control libraries with known DNA 
sequence [92, 99]. Comparing the known sequence with the called sequence could then be 
used to determine the critical detection threshold. 
4.3.2 Advantages and disadvantages of PCR amplification 
The second challenge associated with massively parallel sequencing of the mitochondrial 
genome is the need for mtDNA enrichment. Despite the presence of multiple mtDNA copies 
in each cell, mtDNA only comprises a small portion of the total cellular DNA, making it 
necessary to enrich the samples for mtDNA before sequencing. The most commonly used 
method for enrichment is PCR amplification [52]. Although this method is relatively cheap 
and efficient, it can produce sequencing errors in several ways. Firstly, since high number of 
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amplification cycles is usually needed for sufficient enrichment, PCR can lead to sequencing 
artifacts that may result in false positives [100]. Secondly, PCR may alter the proportion of 
different alleles as not all mtDNA molecules (or segments within a molecule) are amplified 
equally [100]. Lastly, there is the presence of so-called nuclear DNA sequences of 
mitochondrial origin (NUMTs; see below), which are a potential source of contamination 
when PCR is used to analyze mtDNA. Although this problem to a large extent can be solved 
by designing and validating a set of primers that prevents the amplification of nuclear mtDNA 
sequences and specifically amplifies mitochondrial DNA (see 2.5.5), finding the right set of 
primers can be a very labor-intensive task [51]. Moreover, the process of producing and 
validating a consensus compilation of human NUMTs is still ongoing, meaning that new 
NUMTs could be added to the list in the future and old NUMTs could be removed [101]. This 
makes it even more difficult, if not impossible, to completely prevent the amplification of 
NUMTs when PCR is used for mtDNA enrichment. 
For these reasons, we enriched our samples for mtDNA using a reliable protocol involving 
only a conventional plasmid preparation method and purification with paramagnetic beads, or 
followed by 10 cycles of PCR amplification. As shown in Figure 13, when PCR was included 
this resulted in uneven coverage of the mitochondrial DNA with a pattern corresponding to 
the 9 pairs of overlapping primers used to cover the entire mtDNA genome. In contrast, the 
PCR free method resulted in uniform coverage throughout, which is important in order to 
detect and determine the size of large-scale mtDNA deletions. The coverage achieved by 
direct sequencing thus indicates that the PCR free method is the preferred approach when 
analyzing mitochondrial DNA by massively parallel sequencing. 
4.3.3 The presence of nuclear DNA sequences of mitochondrial 
origin (NUMTs) 
The third challenge associated with mtDNA analysis by massively parallel sequencing is the 
presence of mitochondrial DNA sequences in the nuclear genome (NUMTs), which are the 
result of transfer of DNA segments from mitochondria to the nucleus. Although the full 
details of how mitochondrial DNA actually enters the nucleus are not understood, several 
mechanisms have been proposed (Figure 21). To date, approximately 200 NUMTs in the 
human nuclear genome are known [101]. These are evenly distributed within and among 
chromosomes, and up to 90% (14,654bp) of the human mtDNA can be found at a single 
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nuclear locus [102]. However, only about a third of all NUMTs present in the nuclear DNA 
are due to insertions of mitochondrial sequences, the rest being originated as duplications of 
pre-existing NUMTs [103]. Moreover, a subset of NUMTs is highly rearranged, including 
sequences derived from different regions of the mitochondrial genome that have undergone 
inversions, deletions, and duplications [51]. The sequence similarity between NUMTs and 
their corresponding mitochondrial sequences is therefore highly variable, and not a single 
known NUMT is identical to its mitochondrial counterpart [101]. In addition, only a few 
human NUMTs have so far been validated and verified by both in silico and in vitro 
approaches, meaning that the existence of only some NUMTs is confirmed. The existence of 
the rest is more or less probable as determined by various bioinformatics approaches [101]. 
 
Figure 21 Proposed mechanisms of NUMT entrance into the nucleus. For NUMTs to persist in the nuclear genome, 
mtDNA must first physically reach the nucleus and then integrate into the nuclear chromosome, with intragenomic processes 
of amplification, mutation, or deletion following. Work so far has focused on the escape of DNA from the mitochondria and 
on the integration of mtDNA within the nucleus but not on its physical entrance into the nucleus. Although the full details of 
this process are not understood, a few different pathways have been proposed (not all details in the figure are described here): 
A) Abnormal mitochondria are taken up for degradation by the vacuole (in plant and fungal cells). B) Lysis of mitochondrial 
compartment. C) Encapsulation of mitochondrial DNA inside the nucleus. D) Direct physical association between the 
mitochondria and the nucleus and membrane fusion. E) After mtDNA has entered the nucleus, it can integrate into nuclear 
chromosomes during the repair of double-strand breaks in a mechanism known as non-homologous end-joining (NHEJ) 
(adapted from [102]). 
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These facts strongly suggest that NUMTs constitute a real source of contamination when PCR 
is used to study mtDNA. Even if primers are carefully designed to prevent co-amplification of 
nuclear and mitochondrial DNA, we cannot be sure whether some contamination has occurred 
or not since the full list of validated NUMTs has yet to be defined. Therefore, by avoiding 
PCR amplification altogether as we did in this study, we also avoided one important source of 
contamination associated with the presence of NUMTs. When using massively parallel 
sequencing to analyze the mtDNA genome, however, NUMTs constitute still another 
potential source of error as there is the possibility of mtDNA reads being aligned to the 
nuclear genome instead of the mitochondrial DNA target. However, our results demonstrate 
that this possibility is negligible. Figure 22 shows the alignment data of three of the NUMTs 
predicted to be real based on various in silico methods [101]. In all three cases, only a few 
reads, at most 6 at a given position, aligned to the nuclear DNA, while the rest of the reads 
(>40,000 per nucleotide position) aligned to the mtDNA genome (compare with Figure 13). 
These results indicate that the presence of mtDNA sequences in the nuclear DNA does not 
constitute a problem even when the whole human genome is used as reference during 
alignment. 
 
Figure 22 Alignment data for three human NUMTs. The figure shows alignment data for three human NUMTs predicted 
to be real, including the long 14,654bp NUMT. Somewhat surprisingly, only a few reads aligned to the three nuclear DNA 
loci. In comparison, more than 40,000 reads on average per base position aligned to the mitochondrial sequences homologues 
to these NUMTs. The data shown are from the PCR free sample from patient 3. A: m.672-15325/chr4:156592474-
156607061; B: m3819-15924/chr7:57257414-57269467; C: m.724-9666/chr11:102778067-102786933. Nucleotide positions 
refer to the hg18/GRCh38 genome assembly. 
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The reason why so few reads aligned to the nuclear DNA loci may in part be that all NUMTs 
have an incomplete sequence similarity with their mitochondrial homologues. This makes it 
more likely that a read will align to the mtDNA genome than to the nuclear DNA since the 
alignment tool only allows for a limited amount of error. Moreover, the use of paired-end 
sequencing further increases the likelihood that a read will align to the mitochondrial genome. 
For a paired-end read to align to the nuclear genome, both ends of the read must fall within 
the nuclear sequence, making it less likely that the alignment will occur. This is especially 
true for NUMTs shorter than 500bp, as the DNA was sheared with a sonicator to produce 
fragments with an average size of 500bp during library preparation. In any case, our results 
show that the potential problems associated with PCR and NUMTs can be overcome while 
still achieving an ultra-deep and uniform coverage of the entire mtDNA genome, making it 
possible to accurately detect and quantify low-level heteroplasmic mutations.  
4.4 Assessment of mtDNA variants identified in patient 2 
Current molecular diagnostic methods for the detection and quantification of mitochondrial 
DNA mutations are based on the screening for common point mutations followed by 
quantification of the mutation load. If the screening is negative, the entire mtDNA genome is 
sequenced to find causative rare variants or novel mutations [99, 104]. In the current work, 
however, these steps were performed simultaneously, resulting in the identification of 11 
mtDNA single nucleotide variants (SNVs) in patient 2, all of which were nearly homoplasmic 
(Table 19). Predicting the pathogenicity of mtDNA SNVs is a challenging task due to the 
complicated nature of mitochondrial genetics combined with the genetic heterogeneity of 
mitochondrial diseases. Thus, very useful pathogenicity criteria have been proposed for the 
identification of disease-causing mtDNA mutations [105, 106].  
One of these criteria is whether a variant has previously been reported to cause a similar or 
identical phenotype in other individuals. Of the 11 mtDNA variants detected in patient 2, only 
two are reported in the comprehensive human mitochondrial genome database MITOMAP 
(www.mitomap.org), which so far includes almost 600 different mtDNA point mutations 
implicated in disease. The first of the two mutations, the D-loop insertion m.310T>TC, has 
been proposed to be involved in malignant melanoma etiology and pathogenesis [107]; while 
the second variant, the tRNA
Gln
 point mutation m.4336T>C, has been implicated in several 
disorders, primarily Alzheimer’s and Parkinson’s disease [108]. None of these disorders, 
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however, are directly relevant for the clinical phenotype of our patient. The remaining 9 
single nucleotide variants, including the 3 protein-coding variants m.4769A>G, m.8860A>G, 
and m.15326A>G, are all reported in MITOMAP as mtDNA polymorphisms, and are 
therefore unlikely to be the cause of the patient’s phenotype. This conclusion is also 
consistent with the observation that homoplasmic mtDNA point mutations tend to be less 
pathogenic than heteroplasmic mutations due to purifying selection acting on deleterious 
heteroplasmies to keep them at low frequencies [109]. 
Considering this patient’s clinical picture, the most prominent feature of which is the signs 
and symptoms of partial PEO, the genetic cause is most probably a large-scale mtDNA 
deletion. Although a firm diagnosis is yet to be established, PEO is almost invariably 
associated with mtDNA deletions confined to skeletal muscle [66]. Even if the signs of PEO 
are only the first manifestation of a developing KSS, it is expected that the genetic defect 
responsible for the patient’s phenotype is a large-scale mtDNA deletion, which is more easily 
detected in muscle tissue than in fibroblasts, explaining why we did not detect any deletion by 
massively parallel sequencing of fibroblast-derived DNA. In any case, a molecular diagnosis 
for patient 2 is likely to be established by a genetic analysis of skeletal muscle tissue. 
4.5 Detection of mtDNA deletion in patient 3 
DNA isolated from muscle tissue from patient 3 was analyzed at the Nijmegen Center for 
Mitochondrial Disorders (NCMD), revealing the nearly homoplasmic deletion 
m.6211_8681del. This mtDNA deletion is most probably the cause of the Kearns-Sayre 
syndrome like phenotype in the patient (see 1.7). Approximately 90% of KSS patients have a 
large-scale (1-10 kb) mtDNA deletion present in most tissues, although it is often detectable 
in muscle only [66]. The high level of mutant mtDNA molecules present in patient 3 may 
explain the ataxia, ptosis, and especially ophthalmoplegia. Extraocular muscles have a high 
energy requirement, and mitochondria make up approximately 60% of the cell volume in eye 
muscles [67]. To date, 133 different deletions with known breakpoints have been reported in 
the MITOMAP database. The 2.5 kb deletion m.6211_8681del identified in our patient was 
not among the reported deletions. Therefore, we here present another case of KSS caused by a 
novel deletion present in an almost homoplasmic state in the patient’s muscle tissue. 
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The mtDNA deletion m.6211_8681del was also identified in blood leukocytes and skin 
fibroblasts from the patient, and it was estimated to be present in 2.9% and 4.6% of mtDNA 
genomes in these tissues, respectively (see 3.4-3.4.1). As shown in Figure 13, sequencing of 
the PCR-free DNA sample from patient 3 fibroblasts resulted in uniform coverage across the 
entire mtDNA genome, with no visible reduction of coverage between the deletion junctions 
(6211-8681 kb). The low-level deletion heteroplasmy of 4.6% was therefore too low to be 
detected by the deep-sequencing method used in this study. 
4.6 Are fibroblasts suitable for mtDNA analysis by massively 
parallel sequencing? 
It is well known that mitochondrial disorders exhibit clinical and biochemical tissue-
specificity; however, the underlying genetic defects are generally less specific, as the same 
mtDNA defect can be detected in a variety of tissues [110]. While pathogenic mtDNA point 
mutations are often detected in blood leukocytes and, in some cases, also in urinary epithelial 
cells, hair follicles, buccal mucosa, and skin fibroblasts, large-scale deletions are more likely 
found in muscle [110].  
The three main syndromes observed in patients with mtDNA deletions are KSS, chronic 
progressive external ophthalmoplegia (CPEO), and Pearson’s syndrome (PS), the latter being 
a severe systemic illness of childhood associated with sideroblastic anemia (see 1.6.1; 
Footnote 3). Whereas in CPEO, the mtDNA deletion is found exclusively in muscle, in both 
KSS and PS the deletion is usually present in many tissues and can be detected in both blood 
leucocytes and skin fibroblasts [66, 111]. However, the occurrence of heteroplasmy in 
disorders caused by mtDNA deletions can result in varying tissue distribution of 
mitochondrial DNA molecules containing the deletion. Our results showed that the percentage 
of deleted mtDNA in patient 3 was much lower in fibroblasts and leucocytes than in muscle 
cells (see 3.4-3.4.1). A similar tissue distribution of mtDNA deletions have also been 
observed in other KSS patients [112]. The reason for this pattern is unclear, but it has been 
attributed to the frequent cell division of leucocytes and skin cells, allowing selection against 
the survival of cells with deletions in mitochondrial DNAs [112]. It appears, however, that 
this selection is not always very efficient since mtDNA deletions in PS are usually more 
abundant in blood than in other tissues, making the molecular diagnosis of PS reliably made 
by genetic analysis of leucocyte DNA [66]. 
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If possible, the most easily accessed symptomatic tissue should be tested. However, if the 
clinical or family history is suggestive of an mtDNA point mutation, various tissues can be 
analyzed to find the mutation. This is generally also the case when an mtDNA deletion is 
suspected, unless the clinical picture is indicative of either PS or CPEO, in which case blood 
leucocytes and skeletal muscle should be tested respectively. In any case, one should always 
bear in mind that a normal result does not eliminate the possibility of a heteroplasmic 
mitochondrial DNA mutation being present, either in the tested tissue or in another tissue. 
4.6.1 Advantages and disadvantages of using skin fibroblasts for 
mtDNA analysis 
In the present work, cultured human fibroblasts were used to analyze mitochondrial DNA by 
PCR free mtDNA enrichment and ultra-deep massively parallel sequencing. An obvious 
advantage of skin fibroblasts is the ease with which they are cultured and the resulting high 
number of cells that can be obtained. Due to the small size of the human mitochondrial 
genome, having many cells available is an important factor for the complete and accurate 
analysis of mtDNA, especially when PCR amplification is excluded from the protocol. 
However, care must be exercised when culturing fibroblast for study, because cells with 
electron transport chain deficiencies are fragile. They may die in culture, leaving only the 
healthy cells to grow [113]. This may in part explain why approximately half of all children 
with deficits in their muscles have normal enzyme activity in cultured skin fibroblasts [114]. 
In addition, mtDNA deletions tend to be present at low levels of heteroplasmy in fibroblasts, 
making their detection very challenging. But despite these limitations, cultured skin 
fibroblasts remain the choice of preference in some situations because of the ease with which 
they are obtained and handled [115]. Furthermore, adding pyruvate and uridine to the culture 
medium has previously been indicated to allow cells with respiratory chain deficiencies to 
survive, thus preventing false-negative results [113]. 
4.6.2 Analyzing mtDNA from blood leukocytes and skeletal muscle 
When investigating patients with a suspected mitochondrial disorder, peripheral blood is in a 
sense the ideal tissue to analyze because it is obtained in a non-invasive manner. As was 
pointed out, blood leucocytes are the best choice when dealing with cases of Pearson’s 
syndrome, but they can also be useful in detecting mtDNA point mutations and low-level 
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heteroplasmic deletions in general. Moreover, the relatively high concentration of white blood 
cells in normal human blood further suggests that they are suitable for mtDNA studies. In the 
mtDNA enrichment protocol applied in our work, approximately 10 million fibroblast cells 
were used per extraction (see 2.5.1). The normal leukocyte count in adults is 4,000-11,000 
cells per microliter of blood [116], meaning that a 10 mL blood sample gives sufficient 
amount of mtDNA for direct sequencing.  
Despite the invasive nature of muscle biopsies, skeletal muscle remains the tissue of choice 
for genetic analyses of mitochondrial DNA. Because of the great energy requirement of 
muscle cells, they are highly vulnerable to respiratory chain deficiencies. Consequently, many 
of the signs and symptoms most often seen in patients with mitochondrial disorders are 
directly related to muscle [110]. In addition, the relative abundance of mitochondrial DNA 
copies in muscle cells and their retention of mtDNA mutations over time, mean that defects in 
the mitochondrial genome are generally easier to detect in muscle than in other tissues. For 
these reasons, it is desirable to apply the two-step method of Quispe-Tintaya et al. [52] to 
human muscle tissue to prepare samples sufficiently enriched for mtDNA without the use of 
PCR amplification. This method, however, involves the application of a conventional plasmid 
extraction protocol, which is based on the lysis of resuspended cells in solution, and is 
consequently not directly applicable to intact tissues (see 2.5). It is therefore necessary to 
dissociate the muscle tissue into single cells before using the plasmid isolation protocol for 
mtDNA extraction. One way to dissociate muscle tissue is by enzymatic digestion [117, 118].  
4.7 Conclusion 
The main aim of this thesis was to find the genetic causes of the clinical phenotypes of three 
patients with suspected mitochondrial disease. Whole exome sequencing (WES) resulted in 
the detection of the homozygous SURF1 mutation c.106+1G>C, which was verified by 
Sanger sequencing and concluded to be the cause of disease in patient 1. However, no 
mutations were found to be clinically relevant in the two other patients. Therefore, as a sub 
aim of this thesis, a direct deep-sequencing method was used to analyze the whole 
mitochondrial genome of the two patients aiming to identify disease-causing variants. Using 
skin fibroblasts as proof of concept, mtDNA enriched samples were prepared both with and 
without the involvement of PCR amplification. Massively parallel sequencing on the Illumina 
MiSeq platform resulted in a coverage of 10,000-130,000 in all samples, but uniform 
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coverage of the entire mitochondrial genome was only achieved when PCR amplification was 
excluded from the protocol. Because of this, and the fact that PCR is a potential source of 
several sequencing errors, we concluded that the PCR free protocol is the method of choice 
when mtDNA is analyzed by massively parallel sequencing. We also suggest that the same 
protocol could be used on blood leucocytes, both because blood is obtained in a non-invasive 
manner and because a blood sample of normal size contains enough leukocytes for direct 
sequencing. 
Analysis of a muscle sample from patient 3 was performed at the Nijmegen Center for 
Mitochondrial Disorders (NCMD), revealing the nearly homoplasmic mtDNA deletion 
m.6211_8681del. This deletion, which was concluded to be the cause of the Kearns-Sayre 
syndrome like phenotype in the patient, was also a novel finding not previously reported in 
the comprehensive MITOMAP database. In addition, analysis of mtDNA from the patient’s 
blood leukocytes and skin fibroblasts showed that this deletion was present in 2.9% and 4.6% 
of mtDNA genomes in these cells, respectively. However, the low-level deletion 
heteroplasmy of 4.6% was too low to be detected by the deep-sequencing method used in the 
present study. In general, massively parallel sequencing was found to be highly sensitive for 
the detection of low-level (>1%) heteroplasmic single nucleotide variants, but less sensitive 
for large-scale (~2.5kb) heteroplasmic deletions.  
In summary, the genetic defect underlying the clinical phenotype was identified in two of the 
three patients included in this study: the nuclear DNA mutation SURF1 c.106+1G>C in 
patient 1, and the mitochondrial DNA deletion m.6211_8681del in patient 3. The genetic 
defect responsible for the clinical picture of patient 2 remains unknown. 
    
    
 
 
 
68 
 
Supplementary data 
 
Supp. Table S1 Putative pathogenic variants in patient 2 detected by whole exome sequencing and retained after 
filtering.  None of the variants found were considered to be disease-causing. 
Gene name Chr:pos Ref Alt Amino acid change Effect Depth 
MST1L 1:17083807 T C T664A Non-synonymous 43 
MST1L 1:17086870 T C S152G Non-synonymous 28 
PDE4DIP 1:144852477 G A P2235L Non-synonymous 1 
NBPF10 1:145296478 G T D134Y Non-synonymous 7 
HRNR 1:152187562 A C H2181Q Non-synonymous 79 
FCGR2C 1:161569419 C G 
 
Splice site substitution 78 
OR6B2 2:240969483 G A R122C Non-synonymous 58 
POLR2J3 7:102180473 C T R184H Non-synonymous 19 
YWHAZ 8:101965496 C A 
 
Splice site substitution 2 
CNTNAP3 9:39118196 C A G620V Non-synonymous 16 
ORM2 9:117092701 C A P173T Non-synonymous 60 
SFTPA2 10:81319267 C T 
 
Splice site substitution 17 
FAM22D 10:89124914 T A L40Q Non-synonymous 5 
OR8B2 11:124252750 G A L164F Non-synonymous 87 
KIR3DL1 19:55329851 A G Y29C Non-synonymous 44 
PLA2G6 22:38519143 C A G378V Non-synonymous 2 
A4GALT 22:43091638 C A 
 
Splice site substitution 2 
TEX11 X:69828956 A G W312R Non-synonymous 115 
NXF3 X:102334690 C T 
 
Splice site substitution 18 
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Supp. Table S2 Putative pathogenic variants in patient 3 detected by whole exome sequencing and retained after 
filtering.  None of the variants found were considered to be disease-causing. 
Gene name Chr:pos Ref Alt Amino acid change Effect Depth 
RTKN 2:74657626 C T M118I Non-synonymous 127 
PCMTD1 8:52811580 G A P31L Non-synonymous 88 
GJB2 13:20763113 A G I203T Non-synonymous 128 
MST1 3:49725242 C A Q47H Non-synonymous 82 
SFTPA2 10:81319267 C T 
 
Splice site substitution 40 
OR2T10 1:248756470 G C Y200* Stop gained 127 
CYP4A22 1:47608983 G T V185F Non-synonymous 130 
MST1P9 1:17083807 T C T664A Non-synonymous 71 
C7orf28B 7:6859453 C G E214D Non-synonymous 261 
HEG1 3:124774665 G GCAT L23LW Codon change plus deletion 28 
PSORS1C1 6:31106499 G A R37H Non-synonymous 217 
HLA-DRB1 6:32551996 G T A87D Non-synonymous 32 
FCGR2C 1:161565381 A G 
 
Splice site substitution 146 
FCGR2C 1:161569419 C G 
 
Splice site substitution 193 
C14orf57 14:72457365 T G E93A Non-synonymous 127 
ZNF589 3:48289146 G A W25* Stop gained 114 
CACNA2D3 3:54676222 A G D279G Non-synonymous 127 
C10orf93 10:134663933 A G W1923R Non-synonymous 127 
IP6K2 3:48726170 T G N273H Non-synonymous 127 
PTPRS 19:5223204 G A R845C Non-synonymous 127 
PPIP5K1 15:43973324 T C Q292R Non-synonymous 159 
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Supp. Figure S1 Exon 1-5 of SURF1. Nucleotides in bold type indicate the target sequences of the forward and reverse 
cDNA primers in exon 1 and 5, respectively. They gray sequence in exon 1 is the 5’-UTR. The amplicon size is 422bp with 
exon 2 (light blue) and 370bp without exon 2. The sequence depicted is the forward strand shown in 5’-3’ direction. 
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Supp. Figure S2 Distribution of average quality score per sequence for samples from patient 2. Note that there is no 
significant difference in average quality score between PCR and non-PCR samples. P2, patient 2; MP, miniprep; AMP, 
AMPure; PCR, 10 cycles of PCR amplification. 
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Supp. Figure S3 Distribution of average quality score per sequence for samples from patient 3. The non-PCR sample 
results from patient 3 are shown in Figure 15. P3, patient 3; MP, miniprep; AMP, AMPure; PCR, 10 cycles of PCR 
amplification. 
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Supp. Table S3 Mitochondrial DNA point mutations in patient 3 detected by massively parallel sequencing. 
Gene name Position Nucleotide change Amino acid change Effect 
MT-DLOOP 73 A>G 
 
non-coding 
MT-DLOOP 185 G>A 
 
non-coding 
MT-DLOOP 189 A>G 
 
non-coding 
MT-DLOOP 194 C>T 
 
non-coding 
MT-DLOOP 195 T>C 
 
non-coding 
MT-DLOOP 204 T>C 
 
non-coding 
MT-DLOOP 207 G>A 
 
non-coding 
MT-DLOOP 263 A>G 
 
non-coding 
MT-DLOOP 302 A>AC; A>ACC 
 
non-coding 
MT-DLOOP 310 T>TC 
 
non-coding 
MT-RNR1 709 G>A 
 
non-coding 
MT-RNR1 750 A>G 
 
non-coding 
MT-RNR1 1243 T>C 
 
non-coding 
MT-RNR1 1438 A>G 
 
non-coding 
MT-RNR2 2706 A>G 
 
non-coding 
MT-ND1 3505 A>G Thr>Ala non-synonymous 
MT-ND1 3834 G>A Leu>Leu synonymous 
MT-ND1 4093 A>G Thr>Ala non-synonymous 
MT-ND2 4769 A>G Met>Met synonymous 
MT-ND2 5046 G>A Val>Ile non-synonymous 
MT-ND2 5460 G>A Ala>Thr non-synonymous 
MT-TC 5824 G>A 
 
non-coding 
MT-CO1 7028 C>T Ala>Ala synonymous 
MT-CO2 8251 G>A Gly>Gly synonymous 
MT-ATP6 8614 T>C Leu>Leu synonymous 
MT-ATP6 8860 A>G Thr>Ala non-synonymous 
MT-ATP6 8994 G>A Leu>Leu synonymous 
MT-CO3 9591 G>A Val>Ile non-synonymous 
MT-CO3 9920 C>T Ala>Ala synonymous 
MT-ND4 11674 C>T Thr>Thr synonymous 
MT-ND4 11719 G>A Gly>Gly synonymous 
MT-ND4 11947 A>G Thr>Thr synonymous 
MT-ND5 12414 T>C Pro>Pro synonymous 
MT-ND5 12705 C>T Ile>Ile synonymous 
MT-CYB 14766 C>T Thr>Ile non-synonymous 
MT-CYB 15326 A>G Thr>Ala non-synonymous 
MT-CYB 15884 G>C Ala>Pro non-synonymous 
MT-DLOOP 16192 C>T 
 
non-coding 
MT-DLOOP 16223 C>T 
 
non-coding 
MT-DLOOP 16292 C>T 
 
non-coding 
MT-DLOOP 16325 T>C 
 
non-coding 
MT-DLOOP 16360 C>T 
 
non-coding 
MT-DLOOP 16519 T>C 
 
non-coding 
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Supp. Table S4 Summary of the 74 different SURF1 mutations that have been reported to date. 57 of the 74 mutations 
are frameshift, splice site, and nonsense mutations that may result in nonsense-mediated decay of the transcript. The 
homozygous splice site mutation c.106+1G>C (marked in red) detected in our patient has previously been reported 
once in a Pakistani individual with Leigh syndrome. References to all the mutations listed below can be found in 
Lee et al. [66]. Homo, homozygous; Het, heterozygous; NR, not recorder in reference.     
Mutations (n=74) Consequence 
Number of alleles 
(n=248) 
Ethnicity 
    
Frameshift (n=30) 
   
c.37_38ins17 p.V13AfsX65 2 (1 Homo) 1 European 
c.39delG p.A14RfsX57 1 (1 Het) 1 Slovenian 
c.169delG p.E57KfsX15 1 (1 Het) 1 Hispanic 
c.183_186delTCTT p.L62SfsX9 1 (1 Het) 1 Caucasian/ native American 
c.312_321del10insAT p.L105X 45 (10 Homo, 25 Het) 11 European 
   
6 Slovenian 
   
3 Denmark 
   
10 Caucasian 
   
3 NR 
   
1 Sweden 
   
1 Caucasian/ Native American 
c.367_368delAG p.R123GfsX4 2 (1 Homo) 1 Japanese 
c.472_473delAG p.S158WfsX21 1 (1 Het) 1 Caucasian/ Asian 
c.531_534del AAAT p.V177VfsX183 2 (2 Het) 2 European 
c.536delG p.R179KfsX9 2 (1 Homo) 1 European 
c.552delG p.K185RfsX3 5 (2 Homo, 1 Het) 3 European 
c.555_556delGA p.K186SfsX4 2 (2 Het) 2 Caucasian 
c.566delG p.P568LfsX19 1 (1 Het) 1 European 
c.572_573insCCCT p.T192PfsX8 1 (1 Het) 1 NR 
c.574_575insCTGC p.R192PfsX8 9 (1 Homo, 7 Het) 3 European 
   
1 Czech 
   
4 Caucasian 
c.587_588insCAGG p.Q196HfsX4 2 (2 Het) 2 NR 
c.622delA p.R218GfsX1 1 (1 Het) 1 Chinese 
c.653_654delCT p.P218VfsX30 2 (2 Het) 2 Chinese 
c.675_692del18 p.N225NfsX71 1 (1 Het) 1 NR 
c.756_759delCA p.T253SfsX37 3 (1 Homo, 1 Het) 1 European 
   
1 Czech 
c.772_773delCC p.P258HfsX33 3 (1 Homo, 1 Het) 2 European 
c.790_791delAG p.R263SfsX27 3 (1 Homo, 1 Het) 1 Japanese 
   
1 European 
c.800_801insT p.R268QfsX23 1 (1Het) 1 Slovenian 
c.802_827del26insGG p.R268GfsX26 1 (1 Het) 1 Japanese 
c.807_810del4ins9 p.E270QfsX9 1 (1 Het) 1 Asian 
c.812del18 p.H271PfsX1 1 (1 Het) 1 Czech 
c.814_815delCT p.L272AfsX19 1 (1 Het) 1 European 
75 
 
c.820_824dupTACAT p.V276TfsX2 1 (1 Het) 1 NR 
c.821_838del18 p.Y274X 4 (1 Homo, 2 Het) 3 Slovenian 
c.845_846delCT p.S282CfsX9 59 (21 Homo, 17 Het) 28 Slovenian 
   
6 European 
   
1 Denmark 
   
2 Caucasian 
   
1 Caucasian/ Asian 
c.868_869insT p.K291X 4 (2 Homo) 2 European 
    
Splice (n=18) 
   
c.55-1G>A Splice 1 (1 Het) 1 Caucasian 
c.106+1G>C Splice 2 (1 Homo) 1 Pakistani 
c.107-2A>G Splice 1 (1 Het) 1 Caucasian 
c.240+1G>T Splice 6 (1 Homo, 4 Het) 4 European, 
   
1 Caucasian/ Asian 
c.240+1G>C Splice 1 (1 Het) 1 Chinese 
c.323+2T>C Splice 1 (1 Het) 1 European 
c.324-11T>G Splice 2 (1 Homo) 1 Asian 
c.515+2T>G Splice 1 (1 Het) 1 European 
c.516-2_516-1delAG Splice 2 (1 Homo) 1 European 
c.516-2A>G Splice 1 (1 Het) 1 Caucasian/ Asian 
c.588+1G>A Splice 1 (1 Het) 1 European 
c.588+1delG Splice 1 (1 Het) 1 European 
c.603-1G>C Splice 1 (1 Het) 1 European 
c.751+1G>A Splice 1 (1 Het) 1 Sweden 
c.751+6T>C Splice 2 (2 Het) 1 European 
   
1 Caucasian 
c.752-3C>G Splice 1 (1 Het) 1 European 
c.752-1G>C Splice 1 (1 Het) 1 Slovenian 
c.833+1G>A Splice 2 (1 Homo) NR 
    
Nonsense (n=9) 
   
c.74G>A p.W25X 1 (1 Het) 1 European 
c.244C>T p.Q82X 4 (2 Homo) 1 Japanese 
   
1 Turkish 
c.574C>T p.R192X 1 (1 Het) 1 Czech 
c.640C>T p.Q214X 1 (1 Het) 1 Japanese 
c.688C>T p.R230X 11 (3 Homo, 5 Het) 2 Sweden 
   
2 Czech 
   
1 Denmark 
   
1 French 
   
1 Germany 
   
1 NR 
c.751C>T p.Q251X 3 (1 Homo, 1 Het) 2 European 
c.808G>T p.E270X 1 (1 Het) 1 European 
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c.834G>A p.W278X 4 (2 Homo) 2 NR 
c.867G>A p.W289X 2 (1 Homo) 1 European 
    
Duplication (n=1) 
   
c.808_822dup 15 p.269_274dup5 1 (1 Het) 1 Sweden 
    
Missense (n=16) 
   
c.167C>G p.A56G 1 (1 Het) 1 Caucasian 
c.239A>G p.Q80R 1 (1 Het) NR 
c.269T>C p.L90P 2 (2 Het) 2 Caucasian 
c.370G>A p.G124R 3 (1 Homo, 1 Het) 2 European 
c.371G>A p.G124E 1 (1 Het) 1 European 
c.530T>G p.V177G 3 (1 Homo, 1 Het) 1 Hispanic 
   
1 Turkish 
c.539G>A p.G180E 1 (1 Het) 1 European 
c.574C>G p.R192G 1 (1 Het) 1 Chinese 
c.604G>C p.D202H 8 (8 Het) 8 Chinese 
c.608T>C p.L203P 1 (1 Het) 1 NR 
c.614G>A p.G205E 2 (1 Het) 2 Caucasian 
c.704T>C p.M235T 1 (1 Het) 1 Czech 
c.737T>C p.I246T 2 (2 Het) 1 European 
   
1 French 
c.769G>A p.G257R 1 (1 Het) 1 Caucasian 
c.820T>G p.Y274D 1 (1 Het) 1 Japanese 
c.821A>G p.Y274C 1 (1 Het) 1 Czech 
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